Cleveland State University

EngagedScholarship@CSU
ETD Archive
2012

Elastogenic Characterization of Rat BM-MSC-Derived SMCS
Towards Use in Soft Tissue Engineering
Sahithya Wintrich
Cleveland State University

Follow this and additional works at: https://engagedscholarship.csuohio.edu/etdarchive
Part of the Biomedical Engineering and Bioengineering Commons

How does access to this work benefit you? Let us know!
Recommended Citation
Wintrich, Sahithya, "Elastogenic Characterization of Rat BM-MSC-Derived SMCS Towards Use in Soft
Tissue Engineering" (2012). ETD Archive. 627.
https://engagedscholarship.csuohio.edu/etdarchive/627

This Thesis is brought to you for free and open access by EngagedScholarship@CSU. It has been accepted for
inclusion in ETD Archive by an authorized administrator of EngagedScholarship@CSU. For more information,
please contact library.es@csuohio.edu.

ELASTOGENIC CHARACTERIZATION OF RAT BM-MSC-DERIVED SMCS
TOWARDS USE IN SOFT TISSUE ENGINEERING

SAHITHYA WINTRICH

Bachelors of Science Computers and Information Science
Cleveland State University
May 2003

Submitted in partial fulfillment of requirements for the degree
MASTER OF SCIENCE IN BIOMEDICAL ENGINEERING
at
CLEVELAND STATE UNIVERSITY
December 2012

This thesis has been approved
for the Department of Chemical and Biomedical Engineering
and the College of Graduate Studies by

_________________________________________________________________
Thesis Chairperson, Dr. Anand Ramamurthi
Department of Biomedical Engineering, Cleveland Clinic
______________________________
Date

_________________________________________________________________
Dr. Joanne M. Belovich
Chemical and Biomedical Engineering Department, Cleveland State University
______________________________
Date

_________________________________________________________________
Dr. Chandrashekar Kothapalli
Chemical and Biomedical Engineering Department, Cleveland State University
______________________________
Date

ACKNOWLEDGMENTS
I would first like to thank Dr. Joanne Belovich for accepting me into the
Biomedical Engineering program at Cleveland State University and for her continuous
guidance. I would also like to thank Ms. Rebecca Laird (Becky) for keeping me
motivated and Ms. Darlene Montgomery for her help with program logistics. The Choose
Ohio First Program (COFSP) has been instrumental in my educational pursuit by
providing me with financial support. I would like to thank Dr. Jorge Gatica for helping
me obtain this scholarship and funding.
Dr. Anand Ramamurthi has been my guide and support during my research years
at the Biomedical Engineering department at The Cleveland Clinic Foundation. I thank
him for the opportunity for equipping me with skills necessary for a good scientist. In
addition, the lab members of Dr. Ramamurthi were extremely helpful in the completion
of my thesis.
The core services of The Lerner Research Institute were extremely helpful in
teaching me the necessary techniques and helping me analyze data. My sincere thanks to
Ms. Anne Colteur and Ms. Cathy Shemo from the Flow Cytometry Core; Dr. Judy
Drazba, Dr. John Peterson and Mr. Eric Diskin from the Imaging Core for their
generosity and patience during my learning and experimentation process. I also am
thankful for all the friends I gained while at Lerner without whom this experience would
not have been the same.
Finally, I’d like to thank my husband Mr. David Wintrich for believing in me in
every step of the way and being my rock.

ELASTOGENIC CHARACTERIZATION OF RAT BM-MSC-DERIVED SMCS
TOWARDS USE IN SOFT TISSUE ENGINEERING
SAHITHYA WINTRICH
ABSTRACT
The inherently poor capacity of post-neonatal vascular smooth muscle cells
(SMCs) to synthesize elastin and biomimetically assemble elastic matrix structures is a
major limitation to our present ability to tissue engineer functional vascular replacements.
Therefore, we presently seek to ascertain if SMCs freshly differentiated from bone
marrow mesenchymal stem cells (BM-MSCs), are elastogenically superior or comparable
to mature, adult aortic SMCs, which would justify their use as elastogenic cell sources for
vascular tissue engineering. We also seek to determine as to how BM-MSCs
differentiation protocols influence the quality and quantity of elastic matrix deposition.
Rat BM-MSCs treated with PDGF-BB (50 ng/mL) and TGF-β1 (5 ng/mL), were
differentiated on human fibronectin (hFN) coated wells for 7 and 14 days respectively
and number-expanded in the presence of factors for 7 days in uncoated flasks.
Immunohistochemistry data for SMC specific markers showed positive staining for αSMA in PDGF-BB and TGF-β1 (7 and 14 day) treated BM-MSCs compared to controls
where as all the cultures expect expressed Calponin BM-MSCs treated without cytokines
for 7 days. Quantitative analysis revealed that α-SMA is more intensely expressed per
cell in PDGF-BB treated BM-MSCs for 7 days when compared to the other conditions,
whereas, TGF-β1 treated BM-MSCs for 14 days had the highest intensity of antibody per
cell for Calponin. Flow cytometry results indicated that BM-MSCs differentiated with
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TGF-β1, especially for 14 days more intensely express SMC markers, especially a-SMA
compared to other markers. Cell cycle analysis indicated that hFN-coated substrate does
not affect differentiation capacity or BM-MSCs and treated with TGF-β1 exhibit a greater
number of cells in the G1 phase of the cell cycle compared to PDF-BB-treated BMMSCs. Real time polymerase chain reaction (RT-PCR) data show higher expression of αSMA, SMMHC and LOX in BM-MSCs differentiated for 7 and 14 days with and without
cytokines compared to BM-MSCs and the greatest expression in BM-MSCs
differentiated in the absence of cytokines for 14 days. Elastin gene expression was
greatest in the 14 day TGF- β1 treated cultures and there was no difference in gene
expression between treatment or control groups for Caldesmon. Cell proliferation data
showed that 7 day differentiation groups had lower cellular proliferation and BM-MSCs
treated with PDGF-BB and TGF-β1 for 14 days had lower expression compared to
others. Comparing the effect of differentiation time, those cultured for 14 days showed
lower cellular proliferation in all groups except SMCs. Like wise, fold change data
exhibited that TGF-β1 treated BM-MSCs for both 7 and 14 days were far less
proliferative than any other group. BM-MSCs treated with PDGF-BB produced greater
amounts of insoluble and soluble elastin compared to all other groups. No significant
differences between BM-MSCs treated and untreated with cytokines for 7 and 14 day and
control cell lines were found in the amounts of collagen and LOX activity except SMCs.
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CHAPTER I
INTRODUCTION

1.1 Cardiovascular disease
According to the American Heart Association (AHA), over 82.6 million
American adults (1 in 3) are afflicted with one or more types of cardiovascular disease
(CVD). A 40% increase in the prevalence of CVD is estimated by the year 20301. Over
the last 100 years, more deaths occurred due to CVD than any other major source of
mortality in the United States of America (Figure 1.1). In addition to the population
attrition rate, the estimated direct and indirect cost of CVD for 2008 was $297.7 billion
and is projected to triple by 2030 to $818 billion1. Major risk factors that contribute to
CVD are high blood pressure, elevated levels of serum cholesterol, high body mass
index, diabetes mellitus, smoking and obesity. The risk of developing CVD increases
with family history of CVD with the highest increase in risk with the existence of
premature CVD in the family member1.
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Figure 1.1. Major causes of death for all males and females in the United States (2008). A = CVD plus
congenital heart disease, B = cancer, C = accidents, D = chronic lower respiratory disease, E = diabetes
mellitus, F = Alzheimer disease. Source: NCHS/NHLB 1

Atherosclerosis, a major contributor of CVD, is a systemic disease that is
associated with significant morbidity and mortality. It affects multiple vascular beds, in
various large and small arteries as well as those feeding the heart (coronary artery), brain
(carotid artery), kidneys (renal artery), and extremities (peripheral arteries). A classic
characteristic of this disease is the hardening of arterial walls due to the build up of
plaque. Plaque results from the accumulation of fat, cholesterol, extracellular matrix
(ECM) components and other substances such as calcium. This phenomenon can cause
inflammation, scar tissue formation, cell recruitment and cell adhesion. Over time, this
leads to narrowing of blood vessels, causing flow restriction or acute surface thrombus
formation from platelet deposition. The major consequences of atherosclerosis are heart
attack, stroke and aneurysms. The life-threatening effects of this disease have different
outcomes based on the size of the blood vessels. In larger diameter arteries, disease is
brought on because of ischemia to tissues that surround occluded vessels from thrombus
2

formation, embolism, or plaque rupture. Atherosclerosis afflicting smaller diameter
vessels, typically less than 3 mm in diameter, can lead to significant morbidity due to loss
of function in the peripheral limbs or their loss due to gangrene leading to severe post
surgical complications 1–3.
Atherosclerosis can initiate secondary to vascular injury from physical, chemical
or microbial attacks, diseases such as diabetes, poor nutrition or inadequate physical
activity. While some diseases and poor lifestyle choices can be controlled by the
cessation of smoking, diet control and increase in physical activity, the pathogenesis of
atherosclerosis in response to vascular injury result in more life threatening
manifestations of the disease and require more aggressive treatments1.
1.2 Current treatment options and limitations
Several therapeutic and preventative treatment options are available today to help
manage the risk factors associated with atherosclerosis and decrease the incidence of
surgical intervention thereby reducing costs. However, clinical treatment options for
severe debilitating manifestations of the disease including minimally invasive and
surgically invasive procedures have now become available, providing a thrust in the
development of new devices and technologies or improve existing ones.
Therapeutic and preventative treatment options for treating atherosclerosis may be
designated as either primary or secondary. Primary options include cholesterol- and lipidlowering statin therapies, anti-hypertensive therapies such as thiazide diuretics (ACE
inhibitors, α-blockers, calcium channel blockers), aspirin, antiplatelet and anti-thrombotic
agents4. Secondary treatment options often include lifestyle modification strategies such
as weight reduction via exercise and diet control as well as smoking cessation. Current
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trends of therapeutic and preventative treatments often include a combinatory approach in
which several pharmacologic agents (polypill treatments) are administered along with
recommended lifestyle changes. While these have indeed shown to lower the risk factors
associated with of CVD in several clinical trials, high mortality rates and increased
morbidity due to severe CVD events still exist and require additional invasive solutions4.
Minimally invasive procedures to treat cardiologic disorders involve the use of a
stent – stainless steel prosthesis inserted via balloon angioplasty, designed to prop open
the occluded vessel to maintain it patent. While the initial placement of the stent is
minimally-invasive via laparoscopic procedures, the process of catheter insertion often
damages the lumen of blood vessels exposing the underlying cell layers to blood
components with the potential of thrombus formation. Therefore based on the vessel
morphology and clinical situation, its success is temporary with restenosis – a repeat
narrowing of the blood vessel, known to occur in about 30-60% of cases within 6 months
of implantation even though stenting improves cardiac function5. The treatment of
restenosis often requires an additional surgical procedure contributing to significant
morbidity mortality and high costs5.
For small diameter vessels that cannot be treated via angioplasty or larger vessels
that have been severely compromised by disease, bypassing them using vascular graft
conduits may be necessary to maintain blood supply to peripheral tissues/organs. The
gold standard for such grafts has been the use of an autologous tissue source, typically the
saphenous vein or mammary artery. Tissues for such grafts are obtained surgically and
therefore result in morbidity in the area and great patient discomfort. Moreover, the
autologous vascular tissue available for replacement may not be suitable or of sufficient
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length for replacement due to systemic vascular disease in the patient6–8. To overcome
this limitation, allogeneic or xenogeneic (e,g, porcine) vascular tissues may be used for
grafting. Such tissues must however be decellularized and processed to remove donor
epitopes – a part of an antigen recognized by antibodies, and chemically cross-linked to
stabilize as well as preserve matrix structures against enzymatic disruption. The
processing techniques employed can conversely alter tissue mechanics and compliance.
Although decellularization and chemical treatment prevents inflammation and infection,
failure due to size mismatch and graft versus host disease seems inevitable. These
drawbacks have promoted the development and use of synthetic grafts such as Dacron
and polytetrafluoroethylene (PTFE) that sufficiently mimic the mechanical properties of
native blood vessels and elicit a reduced thrombogenic response6.
Synthetic grafts remain less optimal solutions and have several limitations for
replacement in small-diameter vessels. One major drawback is that synthetic grafts are
generally stiffer and far less compliant than naturally available grafts such as autografts,
allografts and xenografts9. This mismatch is a major contributor to adverse long-term
effects such as restenosis and intimal hyperplasia in the region of anastomosis10. Another
critical shortcoming of synthetic grafts is that they have poor capability to endothelialize
in humans beyond the region of anastomosis. The lack of endothelial cells to inhibit
smooth muscle hyper-proliferation, and platelet adhesion, encourages these grafts to
develop a platelet and collagen rich fibrous layer ultimately causing thrombosis5,6. In
large diameter blood vessels (> 6 mm wide) however, thrombosis does not pose as a
major issue since the surface area to volume ratio is low compared to smaller vessels and
blood flow is considerably faster. Consequently, a given thrombus volume occludes a
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much smaller luminal area fraction of the graft relative to a smaller graft. In small
diameter vessels (<6 mm wide), blood flows at a slower rate and is in contact with the
graft for a longer period since surface area to volume ratio is high. A decreased blood
velocity increases the time of interaction between platelets and vascular graft causing
their deposition and contributing to thrombosis5,6. Therefore, a completely tissue
engineered small vascular graft (TEVG) would be highly necessary and desirable.
1.3 Tissue engineered vascular grafts (TEVG) and their limitations
Occlusive plaques afflicting small-caliber vessels are not easily treated
angioplasty, with and without stenting, or bypass synthetic graft procedures, because a)
long, diffuse lesions, and tortuous channels that render the procedures difficult and b)
propensity to thrombose and re-stenose thereby limiting long-term success of the
procedures or performance of the grafts. Tissue engineering has emerged as a promising
approach to address the deficiencies of current options.
Tissue engineering (Figure 1.2), as stated by Langer and Vacanti11 is “an
interdisciplinary field that applies the principles of life sciences and engineering toward
the development of biological substitutes that restore, maintain, or improve tissue
function or a whole organ”11. It utilizes 1) living cells as engineering materials, 2)
scaffolds (biological or synthetic, but biodegradable) to mimic in vivo tissue structures,
enhance cell adhesion, growth or differentiation as well as provide mechanical stimuli to
resident cells, 3) biochemical factors to enhance biological function and 4) bioreactors,
devices that simulate physiological environments by providing controlled culture
conditions including temperature, oxygen and carbon dioxide concentrations, pH and
mechano-transductive stimulation to cells11,12.
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Figure 1.2 A schematic showing the different components of tissue engineering. Source: Wikimedia
Commons; Image available online from http://commons.wikimedia.org/wiki/Main_Page

In vascular tissue engineering, general principles of tissue engineering are applied
to develop tubular constructs known as tissue engineered vascular grafts (TEVG)7. To
produce a TEVG several aspects of the native blood vessels need to be replicated
particularly, its structure and mechanical properties. The cells that become the source of
ECM and biomimetic cues become critical design criteria to fulfill the necessary
requirements of sustained vascular function and tissue structure6,7.
Adult endothelial cells (ECs), smooth muscle cells (SMCs) and fibroblasts have
been used in the last two decades by several groups, to develop TEVG, by culturing the
cells on various types of scaffolds. Collagen, fibrin, decellularized porcine vascular
matrices, and other biodegradable polymer scaffolds including polyglycolyic acid (PGA),
poly(lactic-co-glycolic acid) (PLGA), Polycaprolactone (PCL), poly-L-lactide (PLLA),
and poly-4-hydroxybutyrate (P4HB)6,7,13 have been used as scaffold materials but with
limited success. The inadequate mechanical compliance of the tissue constructs that are
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generated has been a major deterrent to their successful long-term survival. This is due to
challenges in replicating native vessel ECM composition and architecture within TEVGs,
primarily with respect to ECM components such as elastin / elastic fibers that adult cell
types are poorly capable of synthesizing and assembling. Hence in this context, using
terminally differentiated autologous adult cell types can be problematic with the structure
of ECM produced by these cells seldom matching that of during development6,7,13. While
progress has been made with adult cells as sources for TEVG, circumferential alignment
of SMCS, collagen fibers and elastic lamellae is still being investigated. Although some
groups have reported mature elastin fibers by fibroblasts, elastic matrix produced by adult
SMCS is still an open question. Additional limitations of such cells are a) invasive
procedures to obtain healthy vessels for cell isolation, b) difficulties in procurement of
healthy vascular tissues from patients, especially those with synthetic vascular disease,
and c) need for prolonged period of expansion in vitro prior to use for vascular tissue
engineering applications6,7,13. Due to these drawbacks, alternative autologous cell sources
such as stem cells have been considered towards use in generation TEVG.
1.4 Bone marrow mesenchymal stem cells (BM-MSCs) for vascular grafts
The inherently poor ability of adult somatic cells to produce sufficient elastin
precursors and assemble them into matrix structures that mimic that in native vascular
tissues has promoted the study of stem cells as autologous cell sources for TEVG.
Stem or progenitor cells are characterized by their capacity for self-renewal and
differentiation into other specialized cell types under the influence of specific signals and
microenvironments with a phenotype that is distinct from the predecessor14,15. While this
fundamental characteristic yields them the potential for use in cell-based clinical
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cardiovascular treatments and organ regeneration, two other qualities confer ‘stemness’
to these cells. The first is, the expression of specific molecular markers termed stem cell
markers and the second is the ability to execute specialized cell effects14.
The bone marrow is a major source of stem cells in the adult body. The
mononuclear cell fraction of the marrow, a rich source of progenitor cells, can be
obtained by Ficoll-Paque density centrifugation. These progenitor cells are known as
bone marrow mononuclear cells (BM-MNCs) and are heterogeneous populations
containing endothelial precursor cells (EPCs), mesenchymal stem cells (MSCs), HSCs,
and monocytes among others16.
MSCs can be harvested from almost every organ in the body but, due to variations
in differentiation capabilities to specific cell phenotypes and limitations to yield, MSCs
harvested and separated from the bone marrow (typically iliac crest) (BM-MSCs) are the
most commonly used sources of stem cells for developing TEVG14,16,17. They can be
separated from other BM-MNC populations by plating the entire fraction and culturing
only the adherent population or through cell sorting for those with specific surface
markers. They are capable of self-renewal, rapid expansion and differentiation into a
variety of phenotypes such as bone, fat, cartilage, muscle, tendon and cardiovascular cell
types14,16,17. One additional characteristic in their favor is that they are non-immunogenic
in nature when allografted because they lack the major histocompatibility complex II and
have been shown by recent studies to play a role in angiogenesis by the secretion of
various factors to recruit additional stem cells for reparative purposes. Despite the
favorable features, BM-MSCs occupy a tiny fraction of the BM-MNCs (about 0.01%)
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and this percentage and differentiation capability has been shown to decrease with
increasing age 14,16,17.
Several studies have investigated the use of BM-MSCs in vascular tissue
engineering and assessed the patency of TEVG18. In one study, BM-MSCs labeled with
green fluorescent protein (GFP) were seeded onto polyurethane (PU) scaffolds and
surgically implanted into the aorta of a Sprague-Dawley rat. After two weeks, it was
observed that BM-MSCs had proliferated and organized into multiple tissue layers that
mimicked the layers of the aortic wall tissue. Immunohistochemistry showed cells to
express SMC-specific phenotypic markers such as alpha smooth muscle actin (αSMA),
smooth muscle myosin heavy chain (SMMHC), indicating their differentiation, at least in
part, SMCs19. In other work, in vivo transplantation of BM-MSC-seeded electrospun
PLLA conduits into rat carotid arteries showed it to exhibit long-term survival of the graft
due to the non-immunogenic nature of BM-MSCs. Histology showed the MSC-seeded
scaffold to contain newly deposited ECM including collagen and some elastin20.
Despite the above findings, significant unknowns exist in the field, most notably,
the lack of any data pertaining to the ability of BM-MSCs or their derivatives to
synthesize and assemble ECM structures, more specifically, elastin/elastic matrix that are
biological, structural and functional replicates of native vascular ECM, is a serious
limitation to their proposed use for vascular tissue engineering applications. Elucidating
these unknowns is that a critical need towards enabling generation of biomimetic and
functional vascular tissue replacements, and is the focus of the present study.
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1.5 Problem statement and thesis objective
An autologous cell source for TEVG is a potential solution for overcoming
maladies due to CVD such as atherosclerosis. For conditions where the microcirculation
is affected and small-diameter arteries undergo significant damage, TEVG remain the
only hope of treatment. However, since adult vascular cells fundamentally have poor
regeneration capabilities, the use of stem cells for this application seems logical. The low
immunogenic potential of MSCs render them appropriate cell types for tissue
regenerative therapies. Differentiation of MSCs into SMCs has been successfully
demonstrated with past studies. However, the ability of these cells to synthesize elastin
precursors and assemble them into elastic matrix structures that resemble native vascular
ECM, which is crucial to the proper functioning of blood vessels, has not been studied. In
investigating this aspect, we hypothesize that differentiated stem cells would exhibit a
higher elastic matrix regenerative capacity more closely resembling neonatal or fetal cell
populations than adult vascular cells.
The objective of this study is to substantiate prior claims of bone marrow
mesenchymal stem cells (BM-MSCs) as a potential cell source for growing TEVGs. The
specific aims of this study are as follows:
1. Investigate impact of choice of differentiation growth factor and differentiation
time on phenotype of vascular smooth muscle cells derived from rat BM-MSCs.
2. Assess the level of differentiation by biochemical studies testing for SMC specific
proteins.
3. Evaluate the gene expression of SMC specific genes.
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4. Estimate the elastogenic capability of BM-MSCs by measuring the quality and
quantity of elastin synthesized by the differentiated cells.
1.6 Organization of thesis
Chapter 2 provides an overview of the structure and function of the vasculature,
the etiology of occlusive and dilatory vascular disease, treatment options that exist on the
market today, a discussion of TEVG and their limitations, stem cell as elastogenic cell
sources and the characterization of stem cell derived smooth muscle cells.
Chapter 3 provides in detail the experimental methods used for in vitro
differentiation of BM-MSCs and the procedures used to evaluate the successful
differentiation and cell culture. Chapter 4 illustrates results obtained from the
experiments listed in Chapter 3. Chapter 5 provides interpretations of the results from
Chapter 4 and the conclusions to be drawn from this study, and also Chapter 6
summarizes current findings and lists recommendations for future work to further
substantiate the same.
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CHAPTER II
BACKGROUND

2.1 Vascular physiology
The cardiovascular system in animals is unique in its capacity to handle high
blood volumes while maintaining relatively constant systemic pressure throughout the
cardiac cycle due to the presence of large elastic arteries. The capacity of these vessels to
store potential energy due to stretching of the vessel wall during cardiac systole
(emptying of blood by the heart) is crucial to the proper cardiac function. This stored
energy propagates the flow of blood volume downstream to the arterioles during the rest
or filling phase of the cardiac cycle resulting in an even flow throughout the arterial
tree21. To appreciate the mechanism by which vascular homeostasis is maintained in
healthy functioning arteries, it is necessary to understand the underlying components of
the arterial vessels including the cells, ECM constituents and their organization.
The arteries comprise of three major concentric layers or ‘tunics’ delimited by
two sheet-like layers of ECM proteins (membrane limitans interna and membrane
limitans externa). Each tunic contains specialized cells and an ECM of characteristic
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composition and structure22. In order of appearance from the lumen of the artery these
three layers are tunica intima, tunica media, tunica adventitia (Figure 2.1).

B
.

A.

Figure 2.1 The three layers of the artery. (A) Schematic drawing22 (B) H & E stained image of the crosssection
of
a
muscular
artery.
Source:
Color
images
available
at:
http://www.lab.anhb.uwa.edu.au/mb140/corepages/vascular/vascular.htm

Tunica intima
The tunica intima consists of a thin layer of a) squamous endothelial cells
anchored to a basement membrane, b) a thin sheet of subendothelial connective tissue
below the basement membrane and c) an inner limiting membrane that separates the tunic
intima from tunica media. The basement membrane serves as a foundation to anchor
endothelial cells and is comprised of collagen IV, XV and XVIII, laminins and
proteoglycans such as perlecan – a heparin sulfate proteoglycan. The basement
membrane, with the assistance of laminins participates in inflammation by regulating
diapedesis i.e. the migration of white blood cells from the blood stream into adjoining
injured tissue, via the vessel wall. Proteoglycans bind to growth factors and influence
cellular function, such as proliferation of endothelial cells (ECs), and contribute to the
anti-thrombogenicity of the vessel under normal conditions. The ECs secrete various
14

cytokines and growth factors to assist their function: non-thrombogenic and nonleukocyte-adherence factors, vasoconstrictive and vasodilative molecules such as nitric
oxide and other regulatory agents. The major function of the tunica intima lining the
luminal surface of the arteries is to serve as a permeability barrier between blood and
surrounding tissue21–23.

Tunica media
The tunica media is the thickest of the three vascular tunics comprised mostly of
contractile SMCs that generate ECM, including elastin (which forms up to 50% of the
vessel’s dry weight), and collagen types I and III. The vascular SMCs are found
sandwiched between concentric, circumferentially aligned elastic lamellae and
proteoglycan rich ECM. The elastic lamellae, with their ability to stretch and store energy
provide the blood vessel resilience to pulsatile hemodynamic forces during the cardiac
cycle. Collagen, in the media has several important functions- 1) provides tensile strength
to the blood vessel, 2) bears the additional load of mechanical stretching with the elastic
lamellae and 3) prevents vessel overexpansion and resultant rupturing21–23.

Tunica adventitia
The tunica adventitia is the outermost layer of the artery that is mostly made of
fibroblasts connecting the blood vessel to the nearby connective tissue. The adventitia is
surrounded by the vasa vasora, small capillaries that provide nutrients to this layer that is
removed from the blood conducting lumen. The matrix of the adventitia is characterized
by high collagen content and glycosaminoglycans produced by resident fibroblasts. The
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adventitia is the primary load-bearing layer of a blood vessel. The collagen prevents
rupture of the vessel at extremely high pressures21,22.
2.2 Vascular extracellular matrix and mechanics
The vascular ECM is an extensive network present in all three tunics and confers
a blood vessel the unique property of stretch and recoil to accommodate hemodynamic
stresses during pulsatile blood flow. A process of enzymatic degradation and limited new
matrix (matrix turnover) by the resident vascular cells continually maintains the integrity
of the vascular matrix in a blood vessel. Importantly, the structure and components of this
matrix regulate the function, behavior and phenotypes of vascular cells by functioning as
biochemical signaling molecules24. Building a functional matrix requires a concerted
expression of certain genes encoding for ECM proteins secreted out of the cells as well as
enzymes that assemble them to form a network21,22. Of all the extracellular components,
collagen, glycosaminoglycans (GAGs) and elastin are the major players in vascular
structure and function.

Collagen
The most abundant protein in the vascular ECM is collagen which is primarily
responsible for providing tensile strength and structure to blood vessels. Several cell
types produce collagen in the vascular ECM. For example, in the intima and media
vascular SMCs produce this protein whereas in the collagen in the adventitia is produced
entirely by fibroblasts. The collagen protein can polymerize to form ultra structures such
as non-elastic fibers, sheets and fibrils with the distribution varying depending on the
vascular region21,24.
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The collagen family of proteins contains triple helical rod-like domains
constructed by three α chains characterized by a high content of proline, hydroxyproline
and glycine in every third position of the amino acid sequence. In the adult vasculature,
collagen types I, III, IV, V, VI, VIII, XV, XVIII and XIX are found and generally
grouped together based on their structural role – fibrillar, sheet forming, fibril associated
or microfibrillar (Figure 2.2) 21,24.

Figure 2.2 A schematic of collagen monomers and polymers illustrating the assembly of the
macromolecule24.

Fibrillar collagens (types I, III and V) are the most abundantly found protein in
vascular tissue forming networks of fine fibrils and large fiber bundles distributed
throughout the tissue. Monomers of this protein are secreted as procollagen and modified
extracellularly and aligned longitudinally in a staggered arrangement to form fibers.
These fibers are the major structural elements of vascular tissue running longitudinally in
the intima and adventitia and spirally in the muscular media21,24. Sheet forming collagens
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(types IV and VIII) are predominantly found in the basement membrane underlying EC
and basal lamina surrounding SMCs. The monomers of this type of collagen can
associate to form tetramers, which can further interact with other monomers to form a
planar network. Fibril-associated collagens (types XV, XVIII, XIX) also contribute to the
structure of the basement membrane of small and large vessels although; the details of
their function are unknown. Microfibrillar collagens are fine networks underlying the
sheet-forming collagens of endothelial basement membrane. The monomers join to form
tetramers that join end-to-end generating beaded filaments. These are known to serve as
anchor points for other types of collagens21,24.
In addition to providing mechanical support to the vessel wall, collagen in the
adventitia prevents the blood vessel from over extending in response to stretching during
systole. Also, it has been shown that collagen regulates cell attachment and
differentiation. Furthermore, SMCs in a collagenous microenvironment are known to
assume a more contractile and less ECM-generating phenotype21,24.

Glycosaminoglycans
Glycosaminoglycans (GAGs) are polysaccharide chains covalently bonded to
proteoglycans (amino acids associated with sugar molecules). GAGs constitute the
ground substance of the vascular ECM. The bulk of the GAGs are synthesized by
vascular SMCs in response to signaling growth factors such as PDGF and TGF-β21,24 but,
ECs are also known to produce GAGs which are incorporated into the basement
membrane. Hyaluronan, condroitin sulfate, dermatan sulfate and heparin sulfate are
commonly found GAGs in vascular tissue. These polysaccharides are long unbranched
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molecules of repeating disaccharide units with sulfated or carboxylated groups. These
groups render GAGs a high density of negative charge. Thus, GAGs exhibit high affinity
for water, making proteoglycans gel-like structures with the ability to withstand
compressive forces when bound to collagen. GAGs contained in the endothelial basement
membrane give the membrane an overall negative charge, thereby assisting in its
filtration capabilities. Proteoglycans associated with ECs in the luminal surface also
deliver anticoagulant properties to this layer21,24.

Elastin
The major ECM protein that imparts the property of elasticity to blood vessels is
elastin and is mostly present in the medial layer of vascular tissue. The elastic fiber
network of the media is produced by vascular SMCs and organized into concentric sheet
like structures called lamellae within the medial layer of the vessel (Figure 2.3). The
elastin of the lamellae is arranged in fenestrated sheets with collagen fibers, thin layers of
proteoglycan rich ECM and SMCs sandwiched in between. Elastic fibers then connect
the lamellae together into a three dimensional continuous network and to the SMCs21–
23,25

.
The majority of elastic fibers are synthesized and assembled during early

development and adult tissues have limited capability of regenerating this complex
network. Elastic fibers are composed of two distinct components, namely, a core of
amorphous, cross-linked elastin protein, surrounded by electron-dense 10-15 nm long
glycoprotein microfibrils, fibrillin. The fibrillin is first laid down as a pre-scaffold prior
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to coacervation and crosslinking of elastin precursors (tropoelastin). Elastic fibers are
typically 100nm - 1µm in diameter21,26,27.

Figure 2.3 A schematic of a blood vessels showing the distribution of elastin between a muscular artery
(left) and elastic artery (right)25.

Tropoelastin, is a 60-70 kDa protein with hydrophobic sequences alternating with
lysine containing domains. After being secreted into the ECM, tropoelastin precursors
associate with microfibrils forming amorphous cross-linked elastin. Lysyl oxidase
(LOX), an enzyme present in the ECM, further covalently crosslinks lysine residues on
the elastin molecules to other tropoelastin molecules, in the process rendering elastic
matrix structures highly insoluble and resistant to enzymatic degradation (Figure 2.4A).
The elastin molecule has multiple domains – α-helical regions where cross-links are
formed and β sheets with hydrophobic components. The elastic fibers are further linked
to form fiber meshes and continuous or fenestrated sheets21,26,27. These protein domains
can be stretched reversibly, extending up to 220% of their original length (Figure
2.4B)21,22.	
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B.

A.

Figure 2.4 (A) A schematic of elastin synthesis and assembly into elastic fibers27. (B) An elastic fiber
during stretch and recoil with covalently cross-linked domains shown in red28.

	
  
Due to its distensibility, the elastic matrix acts as an elastic reservoir. It has low
tensile strength and distributes stress from mechanical stretching onto collagen lining the
vessel wall (Figure 2.5). These remarkable properties of elastin bestow the vessel its
resilience to the pulsatile pressures. During systole of the cardiac cycle, SMCs in the
media relax, increasing the distance between elastic lamellae and the diameter of the
vessel. Elastic lamellae and fibers store this mechanical energy. In diastole, the opposite
occurs where SMCs contract, reducing the distance between elastic lamellae and
decreasing the diameter of the vessel. The energy stored in the elastic lamellae due to
stretching, is transferred as kinetic energy to blood, propelling it downstream. In addition
to its structural role, elastin regulates vascular SMCs by inhibiting their proliferation and
maintaining them in a quiescent state. The collagen fibers between the elastic lamellae,
provide the vessel with tensile strength and limit vessel expansibility (Figure 2.5)21,22.
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Figure 2.5 Stress-strain curve for a blood vessel29. The stress-strain curve shows the low tensile strength of
elastin accommodating large blood volumes by stretching and high tensile strength of collagen resisting
overexpansion of blood vessel walls with little stretching while bearing the load of high blood volumes.

2.3 Etiology of occlusive and dilatory vascular disease
Atherosclerosis is the most common form of arteriosclerosis, a term that describes
any cardiovascular pathology that involves the occlusion of arteries and calcific stiffening
of their walls, thereby reducing their elasticity. It is a primary source of cerebral and
myocardial infarction, gangrene of the extremities, loss of function of organs and/or
tissues and is a major contributor to the mortality rate in the United States and worldwide.
Over the years, this most widely accepted mechanism for the pathogenesis of
atherosclerosis is the 'response-to-injury' theory (Figure 2.6). Based on this theory,
atherosclerosis is a specialized form of a protective, inflammatory response to various
forms of injury to the arterial wall. Current viewpoints on this theory add that injury to
the endothelium and other vascular cells begin at specific sites in the arterial tree and
characterized by chronic inflammatory response23.
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Figure 2.6 The response of injury model of atherosclerosis. Clockwise from top right: 1) Exposure to
oxidizing agents and and increased monocyte and macrophages adherence 2) cell migration to
subendothelium and lipid accumulation 3) formation of fibrotic lesion 4) development of plaque and
thrombus 5) potential reversal of occlusion with treatment. oxLDL = oxidized LDL 23.

Atherogenesis
Injury to the endothelial lining of the tunic intima initiates the recruitment of
peripheral blood monocytes and T-lymphocytes, which adhere to the luminal
endothelium. Activation of these leukocytes occurs with monocytes converting to
macrophages and T-lymphocytes replicating within the vessel wall. The activated cells
express a series of genes for cytokines and growth factors such as platelet derived growth
factor BB (PDGF-BB), epidermal growth factor, fibroblast growth factor and
transforming growth factor β1 (TGF-β1). These cytokines released into the ECM,
promote the phenotypic change of the quiescent SMCs causing them to proliferate and
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migrate to the region of inflammation where they produce abundant ECM. The final
outcome of this process is the development of plaque in the intima that slowly encroaches
the vessel lumen, forming an atherosclerotic lesion comprised of three major cell
components – synthetic SMCs and lymphocytes in the fibrous cap and macrophages in
the necrotic core and various amounts of lipids and associated lipoproteins. The advanced
form of these lesions are fibrous plaques that can take two forms – an asymmetric
thickening of the intima or symmetric due to an immune rejection such as the placement
of transplanted tissues or devices. Atherosclerotic lesions have shown to progress
becoming occlusive, eventually leading to thrombosis or may be dislodged and travel to
distant vessel as an embolism17,22,23,30,31 .
Injury to the lumenal endothelial lining may have several sources leading to its
dysfunction. Hyperlipidemia, the presence of excessive fats in blood, is the most common
cause of injury. Cholesterol, low-density lipoproteins (LDL) and very low-density
lipoproteins (VLDL) circulating the in blood tend to accumulate at specific sites in the
arterial tree and become oxidized upon uptake by the endothelium. The oxidized lipids
act as chemoattractants and enhance monocyte (macrophages, T-lymphocytes and
leukocytes) recruitment and adhesion to intimal endothelial cells near fatty deposits.
Along with increasing the permeability of vascular tissue to plasma lipoproteins, blood
borne growth factors and oxidized lipids, the resident immune cells recruit more
monocytes to the same region thus triggering an immune response cascade with
infiltrating platelets and contributing to the developing plaque. Other contributors to
atherosclerosis include hypertension, diabetes, poor lifestyle such as smoking and
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consumption of dietary fats or even infectious agents such as viruses or other
pathogens17,22,23,30,31.

The role of SMCs in vascular health and disease
In the developing embryo, vascular SMCs originate from multiple locations.
Coronary artery SMCs are derived from epicardial lining of the mesoderm, SMCs of the
aortic arch are derived from the neuroectoderm and SMCs of the descending aorta are
derived from the local mesenchyme17,32. Regardless of their origin, considerable
differences can be noted in their gene expression patterns32,33. In late embryogenesis and
post-natal development, SMCs are know to be highly prolific, synthesizing ECM
components such as collagen, elastin, proteoglycans, cadherins, and integrins at high
rates contributing to the initial blood vessel structure17,32. In mature adult vessels
however, the resident terminally differentiated SMCs contain the necessary receptors, ion
channels, signal transduction molecules, calcium regulatory proteins, and proteins
necessary for healthy contractile activity important to maintaining vascular tone and
exhibit low proliferation and ECM synthesis17,22.
Vascular SMCs can interchange between the contractile and synthetic phenotypes,
although a continuum exists between the two, under certain physiologic or pathologic
conditions. When the intact vessel is injured these quiescent SMCs are exposed to plasma
constituents and lipids, activating them to a more synthetic phenotype by altering their
gene expression and protein synthesis. Synthetic SMCs migrate from the media to intima,
proliferate profusely and produce abundant amounts of ECM. Their de-differentiation
into a synthetic phenotype is further exacerbated under the influence of cytokines and
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growth factors such as PDGF-BB, TGF-β1 and fibronectin, which are typical for
regenerating tissue. Under their reparative role, SMCs increase their production of matrix
degrading proteins – matrix metaloproteases (MMP) and compromise vessel structure
leading to rupture, thrombosis and embolism formation17,22.
2.4 Treatment options
Preventative and pharmacological treatments
Lifestyle changes often encompass preventative measures to decrease the onset of
atherosclerosis. The consumption of polyunsaturated fats (omega-6 and omega-3) has
demonstrated reduction in the progression of atherosclerosis by reducing inflammatory
molecules31. Foods with a high glycemic index such as refined carbohydrates from grains
and sugars have been associated with the generation of inflammatory markers and
reactive oxidation species leading to diabetes, a high risk factor for CVD31. Diets with
highly refined carbohydrate consumption have been associated with reduced levels of
essential cofactors and antioxidants such as ascorbate, carotene, thiamine, folate,
riboflavin and vitamins A and E31. This deficiency has been shown to contribute to
further injury to the vascular wall under inflammatory driven oxidative stress. Ascorbic
acid has been shown to prevent endothelial dysfunction, inhibit switching of SMCs from
a quiescent to synthetic phenotype, and reduce oxidized LDL uptake and degradation by
macrophages31. Similarly, vitamin E has been held responsible for reducing other
inflammatory markers31. Therefore a diet rich in fruits, vegetables, whole grains,
unrefined sugars and polyunsaturated fats may mitigate the progression of
atherosclerosis. In addition to diet changes, cessation of smoking and increasing daily
physical activity may further help prevent or stabilize atherosclerosis31.
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Pharmacological treatments for atherosclerosis include the use of statins. Statins
target 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase to lower plasma
lipids like cholesterol and inhibit inflammatory cytokines such as IL-1β	
   by	
   affecting	
  
endothelial	
   gene	
   expression31,34.

Additional benefits of using statins are (1) they

improve the production of nitric oxide, an endothelial derived relaxing factor and nitric
oxide synthase, promoting vasodilation (2) inhibit the expression of the vasoconstrictor
endothelin-1 (3) suppress adhesion molecules and cytokine and/or chemokine production
(4) reduce thromogenicity in endothelial cells34.

Endovascular treatments
Endovascular treatments for occluded vessels include percutaneous transluminal
angioplasty (PCTA) and stents. In PCTA, a catheter bearing either a deflated balloon or
laser tip is inserted into the occluded artery. In the case of balloon angioplasty, the
balloon is inflated near the lesion to expand the artery and compact the occluding plaque.
With laser angioplasties, the energy from the laser is used to ablate the plaque.
Alternatively, ablative angioplasty where a co-axially mounted rotating knife removes
plaque build up by the use of opposite low-pressure balloon is used to treat
atherosclerosis5,35.
The use of a self-expanding or balloon expandable stent, i.e., a metal or polymer
mesh covered with polyester fabric, polyurethane or silicone membrane is another
approach to treating atherosclerosis. Stents are often deployed using a catheter in which
the device is stored in a compressed state to be expanded upon delivery to the
atherosclerotic site. Shape memory alloys such as nitinol have been used in the last two
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decades allowing customization of the device to arterial size. In order to prevent an
immune response, drug-eluting stents tethered with antiplatelet and/or anticoagulatory
drugs inhibit neointima formation. More recently biodegradable stents have been
developed to overcome limitations of their metallic and polymer counterparts5,35.

Vascular grafts
In situations where the artery is so diseased that catheters are impassable to treat
stenosis, surgical intervention becomes the only treatment option. Vascular grafts used to
bypass the stenosed arterial segment can be autologous – healthy vessels of comparable
diameter e.g. saphenous veins or synthetic.
Vascular autografts are segments of healthy arterial tissue excised from the
patients themselves and grafted to bypass the diseased or occluded vessel segment. The
gold standard for vascular autografts is the saphenous vein or mammary artery for blood
vessels of the heart or lower extremities. Autografts have several advantages. The bypass
procedure is cost-effective when compared to alternatives. The use of autologous tissue
promotes revascularization and is non-immunogenic in nature. This procedure preserves
the patient quality of life better than limb amputation. However, their availability may be
limited or may not be suitable for certain applications6,8.
For patients whose saphenous vein or mammary artery is unavailable for grafting
from being harvested previously or due to systemic disease, use of synthetic grafts
present an alternative approach. Polymers commonly used for synthetic vascular
prostheses are crystalline, hydrophobic materials that are often reinforced with supporting
rings or coils for long prostheses. Common graft materials include polyethylene
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terephthalate (PET) also called Terylene or Dacron6 and polytetrafluoroethylene
(PTFE)6,8, ordinarily known as Teflon or Gore-Tex (expanded PTFE - ePTFE) its
molecular variant. Other frequently used polymers are polyurethane (PU) and its
variants6.
PET or Dacron is a thermoplastic polymer resin used to make fibers bundled into
yarns that can be woven or knitted into grafting tubes. Tubes made of knitted Dacron can
be infused with proteins such as albumin, collagen or gelatin for decreasing porosity and
easy graft integration, but these effects are temporary with protein degradation occurring
within a short time of grafting. Grafts made of ePTFE are non-textile tubes made by
heating, stretching and extruding. It is more stable in biological systems, less susceptible
to degradation and immune response than PET, but more susceptible to thrombotic
occlusion, especially in smaller diameter vessels6. Polycarbonate-based polyurethane is
stable from degradation due to hydrolysis or oxidation. It promotes endothelization,
reduces amounts of neointimal formation and is better compliant than PET or ePTFE6.
2.5 Limitations of present treatment options
Preventative and pharmacological treatments
Managing risk factors such as diet related obesity, smoking, reduced physical
activity, consumption of refined carbohydrates and sugars undoubtedly help in the
treatment of atherosclerosis but cannot be followed in isolation. While consumption of
foods rich in antioxidants suppresses the oxidation of circulating lipids, this approach is
more of a preventative rather than treatment for severely diseased vessels. The immune
reaction that accompanies atherosclerosis warrants other aggressive treatments31.
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While statins have shown to reduce progression of atherosclerotic plaque by
lowering serum lipid levels, promoting endothelial function by increasing the expression
of vasodilators together with the suppression of vasoconstrictors30,34, they modestly
reduce restenosis3 therefore the need for additional therapies.

Endovascular treatments
Balloon angioplasty temporarily expands diseased vessels and restores blood
flow. However, within six months of the procedure, the vessel lumen is reduced by 50%
and re-stenosis occurs in about half the cases. Implantation of stents/stent grafts reduces
the incidence of re-stenosis but in about 40% of the cases, the condition still persists. The
high cost of this procedure and dangers of restenosis makes this minimally invasive
treatment a less optimal treatment option especially for small diameter vessels5,35.

Vascular grafts
Roughly, 30-40% of the patients needing a bypass procedure lack appropriate
vascular tissue due to prior phlebitis, vessel harvest, varicosities hypo-plasia, or
anatomical mismatch. Even if the autologous tissue was available, severe donor site
morbidity due to surgical removal seems inevitable6. Saphenous vein grafts are liable to
atherosclerosis and intimal hyperplasia for the patency period. To circumvent these
problems, synthetic grafts are frequently used in the present day6.
Even though synthetic grafts are the second best option to autologous sources of
vascular grafts, results are not optimal in terms of healing and tissue regeneration.
Immune response to the synthetic graft is inevitable and begins almost immediately with
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serum protein adhesion, platelet deposition, monocyte recruitment and eventually SMCs
migration, proliferation and ECM production leading to thrombosis and occlusion of the
prosthesis. Despite half a century of development, prosthetic grafts have varied patency
rates. Long-term patency rates in blood vessels larger than 8 millimeters (90% patency
for aorto-iliac substitutes)6,8 are no different for medium-sized vessels between 6-8 mm.
For smaller vessels that less than 6 mm, their outcomes are disappointing with patency as
low as 39% for above the knee bypass grafts when compared to 74% patency rate for
autologous venous bypass6,8.
Synthetic grafts fail due to thrombogenicity and intimal hyperplasia at the distal
anastomosis (the site where the graft is connected to native tissue) developing within the
first year. Compliance mismatch between the rigid prosthesis and compliant artery tissue,
graft and artery diameter mismatch, lack of cellularization of the graft by vascular cells,
surgical trauma and over-proliferation and ECM production by synthetic SMCs
contribute to unsatisfactory results with their use6. Over the years, they have been
improved with coatings of anti-coagulant, anti-thrombogenic and anti-immunogenic
agents. However, neither has prevention of infection nor patency rates improved to a
100%. In order to produce a biocompatible graft, introducing biological components such
as cells to synthetic grafts seem like the most logical choice6.
The requirements of an ideal vascular graft are many. The graft material must be
strong and compliant to withstand long term hemodynamic stresses, non-toxic, nonimmunogenic and non-thrombogenic, biocompatible, easy to handle and suture during
surgical procedures, integrate seamlessly into the host, able to grow with host tissue when

31

placed in children, available off the shelf in various sizes, economical, and have a high
shelf life6.
One method of improving biocompatibility is encouraging the formation of an
endothelial layer inside the graft's lumen. In vivo, post implantation this can occur three
ways - by ingrowth from the native artery from the anastomosed site, vascular tissue
ingrowth through the graft or circulating endothelial progenitor cells. In vitro, endothelial
cells have been seeded onto the synthetic grafts and cultured for 2-4 weeks prior to
implantation. The cell seeded synthetic constructs have been exposed to hemodynamic
forces such as circumferential cyclic stretching, shear stress from fluid flow in the
laboratory to induce structural changes and adaptation prior to implantation. Patency rates
for these grafts have been about 60% and are believed to close the gap between
autologous and synthetic grafts. To improve clinical success, several ECM molecules
such as collagen, laminin and fibronectin have been investigated to support better
adherence of the endothelial layer to the graft6. The incorporation of native matrix
structures that contribute to vessel mechanics such as collagen and elastin are critical for
graft survival and function. Circulating progenitor cells and genetically modified cells
have been considered as alternative cell sources for use with synthetic grafts. While these
constructs improve host integration and patency rates, they still have a limited lifespan
and don't adapt to the changes in native tissue at the anastomized regions6.
2.6 Tissue engineered vascular grafts and their limitations
A living totally-engineered blood vessel (TEBV) or tissue engineered vascular
graft (TEVG) can overcome deficiencies of synthetic grafts with or without biological
components, via their ability to remodel, grow, self-repair and respond to biological
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signals in the vascular tissue microenvironment. Ideally, such as graft would be
composed of cells and ECM arranged in three-dimensional (3-D) layers just as in a native
blood vessel. The lumen of the graft would be lined by an endothelium to prevent
thrombosis, quiescent contractile SMCs circumferentially aligned with elastin or its
analogue for sufficient recoil under hemodynamic forces, and with fibroblasts in the outer
most layer with collagen to provide high tensile strength and support6,7. One underlying
assumption in the design criteria is that the intricate design of native arteries may not be
identically replicated with tissue-engineered constructs7. Several studies have attempted
to produce TEVG with EC, VSMC and fibroblasts seeded within tubes of compacted
collagen gels with Dacron mesh reinforcements for mechanical strength6,7. Four
approaches have broadly tackled the design goals described: 1) decellularized tissues, 2)
synthetic polymer scaffolds, 3) cell sheets via tissue assembly and 4) hydrogels or
biopolymer scaffolds.

Decellularized tissues
Decellularized tissues from autologous sources are composed of natural ECM
with native mechanical properties and biocompatibility. Other scaffold materials used are
decellularized and cross-linked porcine aorta and small intestinal submucosa6. They can
be vascular or non-vascular tissues that have been treated with detergents, enzyme
inhibitors and buffers to remove resident cells and immunogenic epitopes. Although
decellularized vascular tissues grossly retain the structure and composition of native
vessels, treatment conditions cause significant shrinkage possibly due to the stripping of
proteoglycans. Allogeneic decellularized grafts undergo aneurysms, infection and
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thrombosis7. In order to circumvent these issues, decellularized tissues cross-linked with
glutaraldehyde reduces enzymatic degradation but in the process, compromise vascular
mechanics causing stiffening of these tissues. Also, remnants of donor epitopes can
stimulate adverse immune responses and cell debris. Accumulation of cellular debris can
act as focal points for matrix mineralization in the patient leading to tissue stiffening and
rupture6,7.

Synthetic scaffolds
The use of biodegradable scaffolds seeded with vascular cells has been
investigated. One advantage to using biodegradable polymers is the ability to control
scaffolding parameters such as microstructure, mechanical properties, rate of resorption,
and to coordinate the degradation of the scaffold with regeneration of new tissue by
seeded cells, which would seem to take over the mechanics of the construct. Though
polyglycolic acid (PGA) is the most used polymer for tissue engineering applications its
rapid resorption leads to premature weakening of the construct. PGA has been
copolymerized with polylactic acid (PLA), polyhydroxyalkanoate (PHA), poly-4hydroxybutyrate

(P4HB),

polycaprolactone-co-polylactic

acid

(PCL/PLLA)

and

polyethylene glycol (PEG) to overcome this limitation. Since cells are seeded after the
fabrication of these scaffolds to prevent them from apoptosis due to relatively toxic
construction conditions, cell distribution may be severely uneven leading to poor results.
In addition to that failure of the polymer scaffold prior to adequate ECM generation by
the cells can be catastrophic7.

34

Cell sheets
In this approach, different vascular cells are cultured in vitro with factors that
induce ECM production for a period of time and the cell/matrix generated is detached
from the substrates as a sheet and wrapped in layers around a porous tubular mandrel and
conditioned with perfused culture medium. Typically cell/matrix sheets containing SMCs
and fibroblasts respectively are concentrically wrapped around the other and allowed to
fuse together to form a tube with two distinct layers resembling the tunica media and
tunica adventitia respectively. ECs are seeded later along the tube lumen within a
mechanically rotated bioreactor7. Gauvin et. al.36 used a self-assembly approach of tissue
engineering wherein SMCs and fibroblasts were experimented with, in three different
ways. Rolling a single cell sheet of SMCs or fibroblasts separately, rolling the
fibroblastic adventitia on top of the SMCs medial layer and rolling of a single cell sheet
comprising both SMCs and fibroblasts were used to produce the medial and adventitial
layers of vascular tissue. Using this approach, they demonstrated that the single-step
assembly process enhanced ultimate tensile strength, linear modulus and linear modulus
ration when compared to other assembly methods. The single step approach has the
advantage of handling the tissue once reducing the risk of contamination and tear. The
mechanical properties of their constructs were improved by the ECM produced by SMCs
and fibroblasts36. A significant disadvantage in their study is that they did not culture
these in a 3-D environment nor did they investigate the elastic capabilities of these
vessels in response to hemodynamic stresses. The ability of the cells to generate matrix
structures was also not particularly investigated.
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Biopolymer scaffolds
Biopolymer based scaffolds can be designed to provide through contact guidance,
alignment to seeded cells, and through this process, modulate their levels and patterns of
ECM synthesis. Typically, monomers of ECM proteins such as fibrin and collagen are
mixed with vascular cells such as SMCs and allowed to polymerize and compact to
generate cellularized constructs7. When compaction is constrained, fibers of the ECM
protein are generated along the axis of constraint, which provide via contact guidance,
alignment to cells. In this manner, circumferential alignment of cells to mimic that in the
tunica media can be achieved. The poor mechanical strength of these constructs, despite
enzymatic cross-linking of the extracellular monomers by cells is however a problem7.
Addition of growth factors such as TGF-β1 has been shown enhance elastogenesis of
SMCs and improve cross-linking of these matrix proteins within such 3-D constructs to
improve tissue mechanics7,37.
Other approaches to generate biomaterials that mimic vascular ECM fibrillar
structure, viscoelasticity, cell adhesion domains, growth factor binding, and proteolytic
sensitivity have emerged. Electrospinning, a technique in which a polymer solution is
drawn as a fiber onto a rotating mandrel in the presence of a large potential difference,
has been used to produce scaffolds containing defined fiber alignments/orientations.
Although this technique can generate scaffolds containing circumferentially-aligned
fibers, the inability to incorporate cells during the fabrication process and their limited
ability to infiltrate through the closely placed scaffolding fibers, if seeded post-fabrication
is a severe constraint to ensuring cell viability and matrix regeneration within these
scaffolds7.
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Meeting the vascular tissue engineering design requirements seems to be a tall
order today. Constructs engineered by current approaches don't encompass all design
criteria. No approach has demonstrated all the key features necessary in a successful
substitute for the tunica media - circumferential alignment of adult SMCs, collagen fibers
and elastic lamellae. The pursuit of stem cells to produce mature elastic fibers
comparable to that found in native vascular ECM remains a goal of tissue engineering.
Most of the elastin produced so far by tissue engineering is in the amorphous form and
producing elastic fibers circumferentially aligned in a vascular graft remains a challenge.
Therefore tissue engineering with adult stem cells seem promising. For example, Roh et.
al.38 demonstrated that vascular grafts seeded with BM-MNC develop into TEVG driven
by the process of inflammation rather than a stem cell mediated process by the secretion
of monocyte chemoattractant protein - MCP-1. Their findings suggest that stem cells
seeded on vascular grafts act as a source of multiple cytokines that induce angiogenesis,
arteriogenesis and cytoprotection rather than differentiate into vascular cells
themselves38.
2.7 Stem cells as elastogenic cell sources
The ability of the cardiovascular system to accommodate the range of
hemodynamic forces encountered due to pressure and blood volume changes during the
cardiac cycle is due to the complex structure, composition and alignment of ECM and
associated cells within vascular tissue. Elastin, a major component of this matrix confers
blood vessels their elasticity, serves as a framework for adherence of resident SMCs, and
regulates their phenotype via biomechanical transduction, while providing tissue
elasticity,

to

maintain

cardiovascular

homeostasis.
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Unfortunately,

terminally

differentiated adult SMCs are inherently poor in synthesizing elastin precursors and
assembling and cross-linking them into mature elastic fibers and further into functional 3D matrix structures. This becomes a serious limitation to our ability to grow elastic
matrix-rich vascular replacements that resemble native tissues.
Small diameter vascular grafts suitable to replace blood vessels less than 6
millimeters are the target of current tissue regeneration research39. The limited
availability and expandability of adult vascular cells, specifically SMCs and their poor
capacity to biomimetically regenerate elastic matrix structures either in vivo at sites of
proteolytic disease, or in vitro culture, have led to the investigation of stem cells
alternate, more elastogenic cells sources for tissue engineering. The ability of stem cells
to self-renew and to differentiate into daughter cells of with specialized function such as
SMCs renders them useful to investigate as alternate SMC sources18,40.
Stem cells are of several types, e.g. embryonic stem cells (ESCs) or embryonic
germ stem cells, induced pluripotent stem cells (iPSCs), and tissue-resident or adult stem
cells14,17. ESCs are obtained from embryos resembling a hollow sphere comprising 200 to
250 cells known as blastocytes. Embryonic germ stem cells come from 5 to 9 week old
fetuses that can develop into ovaries or testes. ESCs have a unique ability to differentiate
into all cell types of an adult organism and therefore are known as totipotent stem cells.
iPSCs are a result of reprogramming adult differentiated cells (e.g. fibroblasts) into a
state of pluripotency, which indicates that they can be differentiated into most if not all
possible cell lineages. Adult stem cells, can originate from the umbilical cord, placenta,
blood, bone marrow, skin and other tissues14,17. Those that reside in the in bone marrow,
peripheral blood and umbilical cord are termed hematopoietic stem cells (HSC). Those
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residing predominantly in the bone marrow stroma where they are maintained a quiescent
stem cell pool, are termed bone marrow mononuclear cells (BM-MNCs). Each stem cell
type has its advantages and limitations. ESCs can cause tumorogenesis and raise ethical
issues with their procurement form fertilized human embryos, even though this allogeneic
source is able to differentiate into any cell type desired. iPSCs are a better source due to
their autologous origin that enables patient customized therapies with their ‘embryoniclike stemness’ and the lack of ethical issues pertaining to their sourcing, although a lack
of robust characterization to date limits their use. Therefore, autologous or allogeneic
adult stem cells seem the logical choice for use in tissue engineered cell therapies14,17.
BM-MSCs are a favorable source for tissue engineering and regenerative
therapies because of their relative ease of isolation, high expansion ratio, low
immunogenicity, antifibrotic and antiapoptotic propertries, and release pro-angiogenic
factors18,40. They have the ability to differentiate into various cell types including SMCs
or ‘SMCs-like’ in vitro and in vivo18,39–41. Several approaches have been attempted
including differentiation media, growth factors such as PDGF-BB and TGF-β40 and
material used for the vascular construct. Additionally, since their microenvironment
greatly affects their differentiation and matrix production, parameters such as soluble
signaling factors, substrate topography and rigidity and mechanical stimulation can be
used to control the differentiation outcomes and the quality and quantity of matrix
production18.
The ultimate characteristic of a full functioning TEVG is an elastic biological
prosthesis that provides the mechanical properties of the native blood vessels it is sought
to replace. In an attempt to produce just that, several groups investigated the potential for
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differentiation of BM-MSCs into vascular SMCs. However, very little information is
available regarding the matrix synthesis capabilities of the derived cells, and that relative
to adult SMCs, particularly with regard to elastic matrix.
The major factors contributing to successful vascular differentiation of BM-MSCs
isolated from BM-MNCs are the culture conditions, scaffold or substrate properties,
exogenous cytokine addition, mechanical forces resident in the environment (in vitro or
in vivo) and genetic modification. Several scaffolds have been used to construct TEVG
seeded

with

MSC

such

as

decellularized

allogenic

grafts,

polyurethane,

polylacticglycolic-acid16 and polyesterurethane42. Substrates coated with extracellular
components such as collagen-coated acrylamide gels43, tissue culture dishes coated with
laminin (LM), collagen type IV (Col-IV), fibronectin44 have been used to differentiate
BM-MSC to vascular smooth muscle cells (SMCs). Variations in the culture medium
formulations composing of different serum concentrations, cytokines, vitamins and
minerals abound to coax BM-MSC towards vascular SMCs differentiation33,43. The
stiffness of the matrix upon which BM-MSC are cultured can influence and determine the
differentiation and commitment toward a specific cell lineage. The matrix strength is also
a factor that contributes to the amounts of ECM produced by the differentiated cells43.
Shear stress by incorporating flow of culture medium within these grafts when cultured in
vitro, is used to mimic the hemodynamic forces that native vessels experience16. In
addition to the nutrient rich media, several cytokines have been added to BM-MSC for
differentiation toward SMCs – bone morphogenetic protein 242, all trans-retinoic acid45,
transforming growth factor beta-133,46, ascorbic acid46, platelet derived growth factorBB33, transforming growth factor beta-341. Genetic modifications of BM-MSC to express
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endothelial nitric oxide synthase (eNOS) at native vessel levels have also been tried to
confer further antithrombogenic properties16.
Tamama et. al.39 showed that blocking the ERK/MAPK pathway up-regulates
SMCs gene expression in BM-MSC. The ERK/MAPK is an extracellular signal regulated
protein kinase or mitogen activated protein kinase pathway that is anti-myogenic.
Inhibition of this pathway in BM-MSC demonstrated the expression of SMCs specific
genes such as α-SMA, SM22, Calponin and Smoothelin and associated proteins. This
study also showed that BM-MSC have the capability of expressing elastin a pivotal ECM
protein for vascular regeneration. Further, this group showed that PDGF-BB inhibits
SMCs specific gene expression in BM-MSC39.
Wu et. al.47 investigated the effects of graft material on BM-MNC differentiation
into SMCs and the quantity and quality of ECM production. Four different types of
scaffolds – poly(lacticide-co-glycolide), poly(glycerol sebacate) (PGS), PGS coated with
platelet poor plasma and PGS coated with platelet rich plasma, were studied. After 21
days of BM-MNC culture in a bioreactor on these substrates, SMC-specific gene
expression and protein production was assessed. The platelet-rich PGS showed
significantly increased cell proliferation and insoluble elastin content when compared
with the other scaffolds. The collagen content remained the same among all four
constructs as well as the expression and production of SMCs specific genes and proteins
such as Calponin and α-SMA. Their study demonstrated the guidance of BM-MNC into a
SMCs phenotype with characteristic ECM production, namely elastin by mechanical
properties of the scaffold47.
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Gong and Niklason48 studied the ability of human BM-MSCs (hBM-MSCs) to
differentiate into SMCs in both a two dimensional and three-dimensional environment
using several experiments. For the 2-D cultures, hBM-MSCs were grown on tissue
culture plastic using several experimental conditions - addition of TGF-β1 and PDGF-BB
in various concentrations to culture medium; use of treated 6-well plates coated with
collagen types I, IV, elastin, fibronectin and laminin and subjection to cyclic strain. For
the 3-D cultures, hBM-MSC were conditioned with growth factors and seeded on PGA
scaffolds in a bioreactor to form an artificial blood vessel. SMCs differentiation was
assessed for tissues cultured in the 2-D environment whereas ECM proteins such as
collagen and elastin were investigated via Massaon Trichrome and Movat histology
staining in tissues form the 3-D vessel. In the presence of TGF-β1, 2-D cultures showed
increased expression of a-SMA, Calponin but not SMMHC indicating an immature
SMCs state. PDGF-BB treated cells showed reduced expression of the same proteins.
None of the matrix proteins coated on the 6-well culture plate had an effect on hBMMSC proliferation and no difference was found between groups for α-SMA expression.
The 3-D cultures did not reveal positive staining for elastin via the Movat stain nor
tropoelastin monomers were found via Western blots. The results of this study suggest a
partial differentiation of hBM-MSC to SMCs and therefore the lack of elastin or its
monomer48.
In an in vivo study, Sata et. al.49 demonstrated the contribution of BM-MSC
recruited after vascular injury to the atherosclerotic lesion. Specifically, they
demonstrated that BM-MSC undergo differentiation in to a SMCs-like phenotype and
produce ECM proteins including elastic lamellae.
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2.8 Characterization of bone marrow mesenchymal stem cell derived smooth muscle
cells
Successful differentiation of BM-MSC into SMCs has been monitored through
the expression of genes for vascular SMCs cytoskeletal and contractile proteins. The
most frequently examined are smooth muscle alpha actin (α-SMA), calponin, smoothelin,
SM22α and smooth muscle myosin heavy chain (SMMHC) isoforms21. In the developing
phenotype of SMCs, α-SMA is considered an early SMCs marker, calponin, smoothelin,
SM22α are considered mid-stage markers and SMMHC is a late or mature SMCs
marker21,32.
α-SMA is one of six isoactins, which are products of separate genes with high
degree of homology, expressed in mammalian cells. It is the most abundant of the actin
isoforms in mature fully differentiated vascular SMCs and contributes to 40% of total cell
protein. Vascular SMCs have the capability of generating the necessary	
   force for
contraction because of this cytoskeletal protein. Smooth muscle α-actin is also the first
known marker expressed in differentiated SMCs during vasculogenesis and is the protein
that can be detected the earliest. As vascular tissue develops, α-SMA is expressed at
increasing levels by vascular SMCs. The expression of this protein is not limited to
vascular SMCs because it can be expressed transiently by a variety of mesodermally
derived cells such as cardiac and skeletal myocytes as well as myofibroblasts. Therefore,
α-SMA alone is not an indicator of SMC differentiation32.
Calponin is a 28 to 34 kilo Dalton protein that interacts with f-actin and
tropomyosin in the absence of Ca2+ and with calmodulin in the presence of Ca2+. It also
inhibits actin-activated Mg2+-ATPase activity of myosin regulating the contraction of
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vascular SMCs. SM-22α is a 22-kilo Dalton protein containing sequence motif
homologous to calponin but is not associated with the contractile machinery of SMCs. In
adult organisms, this protein is exclusively found in SMCs. Calponin has been detected
relatively late in the development of the organism32.
SMMHC is an essential component of the contractile machinery and shows a high
degree of specificity in both mature and developing organisms. This protein is highly
specific to SMCs and therefore its detection shows a great degree of differentiation
toward SMCs and commitment to a SMC lineage32.
The characterization of SMC-specific cytoskeletal markers is done using multiple
methods. Real time polymerase chain reaction (RT-PCR) detects mRNA for the SMC
specific proteins described above suggesting SMCs specific gene expression. Western
Blots detects the presence of SMCs specific proteins suggesting that the mRNA
transcribed was translated. Immunolabeling with antibodies specific for SMC proteins
allow the visualization of these markers.
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CHAPTER III
METHODS
All experiments of differentiation were based on the work done by Ross J.J. et al33
and Breyer A. et al 50.
3.1 Rat bone marrow mesenchymal stem cells (BM-MSCs) culture
BM-MSCs culture. Passage four mesenchymal stem cells (MSC) (1.0 × 106 cells)
isolated from the bone marrows of adult Sprague Dawley (SD) rats, were purchased from
Invitrogen (Carlsbad, CA). These cryopreserved cells were propagated and passaged in
accordance with the protocol shipped by Invitrogen using rat MSC growth medium
containing D-MEM low glucose medium, 10% v/v MSC-qualified fetal bovine serum
(FBS) (Invitrogen), and 1% v/v antibiotic antimycotic solution (Fisher Scientific,
Hampton, NH). The thawed cells were transferred from the cryovial to a 50-mL sterile
tube. Pre-warmed MSC growth medium (10 mL) was added dropwise while swirling the
tube to mix. The cell suspension was centrifuged for 5 minutes at 300 × g, the
supernatant aspirated, and the cell pellet re-suspended in 5 mL of rat MSC growth
medium. A 100 µL aliquot of the cell suspension was mixed with an equal volume of
Trypan Blue, which is taken up by non-viable cells, and counted on a hemocytomer, to
asses viability. Four T-75 flasks were then seeded at a density of 2.25 × 105 cells per
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flask (area of 75 cm2) and cultured in rat MSC growth medium at 37 °C for 24 hours. The
medium was replaced after 24 hours and every two days thereafter for up to five days.
The cells were then detached from the substrate with 5mL of trypsin added per flask, and
incubated for 5 minutes at 37 °C, mixed with fresh medium prior to centrifugation (1000
× g, 10 minutes) to pellet cell. After aspirating off the supernatant, the cell pellet was
gently pipetted to generate a homogenous suspension. Using a hemocytometer the cell
viability and total cell count was determined as described above. One million cells per
vial were cryopreserved using freezing media containing 60% v/v D-MEM low glucose
medium, 30% v/v MSC-qualified FBS and 10% v/v dimethyl sulfoxide (DMSO;
Invitrogen) as described by the protocol from the company.

Differentiation of rat BM-MSCs into SMCs and their propagation. Cryopreserved
passage 5 BM-MSCs were thawed in a 37 °C water bath and centrifuged at 300 × g.
They were then seeded on six commercially purchased human fibronectin (hFN, 100
ng/mL)-coated 25 cm2 tissue culture plastic flasks (T-25) (BD Biosciences, East
Rutherford, NJ) at a density of 3 × 103 cells/cm2 in 5 mL of differentiation medium
containing components listed in Table 3.1.
Component
Volume (mL)
Final Concentration
DMEM-low glucose
281.66112
60% v/v
MCDB-201
187.77408
40% v/v
FBS
10
2% v/v
Penicillin-streptomycin
5
1% v/v
ITS
5
1×
LA-BSA
5
1×
Ascorbic Acid (0.01M)
5
10-4M
Dexamethasone (20µg/mL)
0.0098
10-9 M
EGF (1mg/mL)
0.005
10 ng/mL
PDGF-BB (100µg/mL)
0.05
10 ng/mL
LIF (106 units/mL)
0.5
103units/mL
Table 3.1 Components of the medium used to differentiate BM-MSCs into SMCs and their individual
concentrations and volumes.
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Passage 4 rat aortic smooth muscle cells (SMCs) and BM-MSCs were seeded
with the same density on four other uncoated T-25 flasks as positive and negative control
cell types for assessment of differentiation of the BM-MSCs. DMEM-F12 medium
containing 10% v/v FBS (Hyclone, Waltham, MA) and 1% v/v antibiotic antimycotic
solution (Medium A) was used to culture SMCs and D-MEM low glucose medium
containing 10% v/v MSC-qualified FBS and 1% v/v antibiotic antimycotic solution
(Medium B) was used to culture the BM-MSCs. Cells in all ten experimental cases
(Table 3.2) were conditioned for 24 hours with the respective media types as described
earlier.
Cell Type

Medium

Substrate

Duration of
Culture

Differentiation Phase on T-25
BM-MSCs

Medium B

Uncoated

7 day

14 day

SMC

Medium A

Uncoated

7 day

14 day

Differentiation media + No factors

hFN coated

7 day

14 day

Differentiation media + PDGF-BB (50 ng/mL)

hFN coated

7 day

14 day

Differentiation media + TGF-β1 (5 ng/mL)

hFN coated

7 day

14 day

BM-MSCs +
No Factors
BM-MSCs +
PDGF-BB
BM-MSCs +
TGF-β1

Propagation Phase on T-75
BM-MSCs

Medium B

Uncoated

7 day

SMCs

Medium A

Uncoated

7 day

BM-MSCs +
Medium A + No Factors
Uncoated
7 day
No Factors
BM-MSCs +
Medium A + PDGF-BB (50 ng/mL)
Uncoated
7 day
PDGF-BB
BM-MSCs +
Medium A + TGF-β1 (5 ng/mL)
Uncoated
7 day
TGF-β1
Table 3.2 Summary of the differentiation and expansion experiments, treatment conditions, growth
substrate, medium used and duration of cell culture.

The BM-MSCs cultured on hFN coated T-25 flasks were differentiated for 7 and
14 days in the above differentiation medium in the presence of exogenous platelet
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derived growth factor BB (PDGF-BB; 50 ng/mL; R & D Systems, Minniapolis, MN) and
transforming growth factor β1 (TGF-β1; 5 ng/mL; Peprotech, Rocky Hill, NJ) or in their
absence. The control cell types were cultured for the same period with the prior specified
respective medium types. During the 7 or 14 day period of differentiation or culture,
spent medium was exchanged for fresh pre-warmed medium along with growth factors
where applicable, every two or three days. At the end of each designated period of
differentiation, the cells were trypsinized, divided into three equal aliquots, and re-seeded
into three uncoated T-75 culture flasks for further propagation. Growth factors where
applicable were added with Medium A for SMCs and differentiated BM-MSCs whereas
the BM-MSCs control was treated with the same media used in the differentiation culture
period (Medium B). Media was changed every two to three days.

Cell culture harvest. After expanding the differentiated cells over a further of 7 days,
each group of cells were trypsinized, and the cell viability and total cell count determined
in each case. Sterile tissue culture 6-well plates (area of 9.6 cm2) were seeded with the
harvested cells at a density of 3 × 104 cells/well and cultured for 21 days for phenotypic
analysis and ECM characterization respectively.
Figure 3.1 summarizes the methodology used for the differentiation, propagation
and biochemical experiments.
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Figure 3.1 Schematic of the differentiation, expansion and biochemical experiments.

3.2 Immunofluorescence –based detection of phenotypic cell markers
Cell culture. After the expansion phase, BM-MSCs that had been cultured with and
without differentiated growth factors for 7 and 14 days, and BM-MSCs and SMCs
cultured for 7 and 14 days were trypsinized and seeded at a density of 3 × 104 cells on
sterile glass cover slips (area of 7.2 cm2; Fisher Scientific) placed within 6-well plates.
Medium A was used to culture SMC and differentiated BM-MSCs, while Medium B was
used to culture the BM-MSCs (control cell type). Cells were cultured for 7 days with
medium changes every 2-3 days.
Sample preparation. After 7 days of culture, the spent culture medium was carefully
aspirated from each cell layer and cells fixed with 4% v/v EM-grade paraformaldehyde
(Polysciences Inc., Warrington, PA) diluted in 1× PBS (25 °C, 15 minutes). The fixative
was then removed, the cell layer gently rinsed with 1× PBS (3 cycles), and blocked and
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permeabilized with PBS (1×) containing 3% v/v goat serum (VWR, Radnor, PA), 0.3%
v/v Triton-100X detergent (25 °C; Sigma-Alderich, St. Louis, MO). Prior to use,
processing solutions were filtered using a 0.22μm vacuum filter to sterilize and remove
any debris that may contribute to background in the staining process. Primary antibodies
purchased from Abcam (Cambridge, MA) were diluted in the blocking and
permeabilization buffer according to the concentrations determined via prior titration
experiments (Table 3.3).
Primary antibody

Host

Concentration (v/v)

Clonality

Smooth muscle alpha actin (αSMA)

Rabbit

1:500

polyclonal

Calponin

Rabbit

1:500

monoclonal

Smooth muscle 22 alpha (SM22-α)

Rabbit

1:100

polyclonal

Smooth muscle myosin heavy chain
Rabbit
1:50
polyclonal
(SMMHC)
Table 3.3 Summary of primary antibody concentrations used for immunoflourescence.

Antibody labeling was conducted in a humidity chamber. Diluted primary
antibody solution (250 μL) was carefully added to cover the entire surface of each cell
layer for each treatment condition and cell type. An equal volume of blocking and
permeabilization buffer was added to one cell layer for each treatment as a negative
immunolabeling control. Primary antibody labeling was conducted overnight at 4 °C.
Following this, the primary antibody solution was pipetted off, the cell layers rinsed with
1× PBS (3 cycles) and then incubated (37 °C, 1 hour, dark) with solutions containing
secondary antibodies conjugated with Alexafluor 594 (Invitrogen), a donkey-anti-rabbit
immunoglobulin (λexcitation = 590 nm and λemission = 617 nm) diluted in the blocking and
permeabilization buffer at a concentration of 1:1000. Finally, the cell layers were rinsed
with 1 × PBS (25 °C, 3 cycles) and then mounted onto glass microscope slides with
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Vecta shield mounting medium containing the nuclear dye DAPI (Vector Laboratories,
Burlingame, CA). The mounted slides were blotted on paper towels for 30 minutes and
once dried, sealed with nail polish on the edges of the glass cover slips.

Qualitative analysis. Composite images for cells labeled with fluorescent antibodies were
obtained using a phase contrast Leica DMR upright fluorescence microscope (Leica
Microsystem, Buffalo Grove, IL) and imaged with an attached digital CCD camera
(Princeton Instruments, Acton, MA) set to Texas red to visualize intracellular SMC
specific proteins such as α-SMA, Calponin and SM22-α. The DAPI-stained nuclei were
visualized via an Ultraviolet laser and blue filter. For each primary antibody, at least n ≥
3 images were obtained after scanning the entire slide and identifying areas with the
greatest density of cells and staining. The exposure time, gain, offset and gamma settings
were chosen based on an initial qualitative comparison of antibody staining among SMC
positive control, BM-MSCs treated with NF, PDGF-BB and TGF-β1. The settings were
consistent

for

all

experimental

conditions

for

each

primary

antibody.

All

immunofluorescence images for BM-MSCs treated with or without growth factors (NF,
PDGF-BB and TGF-β1) were obtained at 40× magnifications whereas those for SMCs
were obtained at 10×.

Quantitative analysis. For quantitative analysis of the immunofluorescence results,
images taken with the same parameters for qualitative analysis were saved in a separate
folder with images for the nuclei (DAPI) and antibodies of interest as separate file names.
The saved images were analyzed with ImagePro® software (Media Cybernetics,
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Inc., Bethesda, MD) for four measurements: 1) average area of fluorescence in the field
of view (FOV), 2) the average density or intensity of staining in the FOV, 3) percent area
(per area) – a ratio of the average area stained to the total area in the FOV and 4) nuclei
count – the total number of cells in the FOV. The software measured all four parameters
based on the number of ‘objects’ it counted per image. An object is defined as any
continuous group of pixels positive for the desired parameter and object number in
ImagePro® does not equal cell number. Percent area measures the ratio of the area sum of
objects and total area sum of the image. Statistics such as mean, standard deviation,
minimum and maximum values were collected using the ImagePro® software.
3.3 Flow cytometry
BM-MSCs, SMCs and BM-MSCs differentiated over 7 and 14 days, were
expanded for 7 days and analyzed by flow cytometry (FC) for extent of expression of
BM-MSC surface markers as well as SMC-specific intracellular markers (Table 3.4). All
antibodies were purchased either pre-conjugated with a secondary fluorophore or with a
conjugation kit and were first titrated with a positively staining cell type to determine
optimal working volumes for each (Table 3.4).

Ab

Function

Preconjugated
fluorophore

Working
volumes
(µL)
BM-MSC surface markers

CD 29

Integrin β1
protein

Alexa Fluor
488

Hamster
(IgG)

CD 90

Thymocyte1 antigen

Brilliant
Violet 421

Mouse
(IgG1)

Excitation
(nm)

Emission
(nm)

1

488

519

1

405

421

492

520

Host

Source

BioLegend,
San Diego,
CA
BioLegend,
San Diego,
CA

SMC intracellular markers
αSMA

Contractile
protein

FITC

Mouse
(monoclonal)

52

2.5

Abcam,
Cambridge,
MA

Ab

Function

Preconjugated
fluorophore

Host

Working
volumes
(µL)

SM22-α

SMCspecific cell
shape
protein

PE-Cy7
(LightningLink PE-Cy7
antibody
labeling kit)

Primary
antibody Goat
(polyclonal)

1.28

565

767

SMMHC

Contractile
structural
protein

Alexa Fluor
647

Mouse
(IgG1)

1.25

633

668

Excitation
(nm)

Emission
(nm)

Source
1°Ab: Abcam,
Cambridge,
MA
Conjugation
kit: Novus,
Littleton, CO
eBioscience,
San Diego,
CA

Table 3.4 Flow Cytometry antibodies used to analyze the extent of BM-MSC and SMC specific markers.

Cells from each treatment condition after the propagation phase were detached
using trypsin and centrifuged (600 × g, 8 minutes, 25 °C) to pellet the cells. The
supernatant was aspirated and the cell pellet was re-suspended in 10 mL of 1× PBS with
1% w/v bovine serum albumin (BSA), re-centrifuged, resuspended in 10 mL of 1× PBS
with 1% v/v BSA, and incubated (25 °C, 15 minutes). A count was performed for viable
cells and 1 × 105 cells were dispensed per eppendorf tube per treatment condition.
Additional tubes with BM-MSCs and SMCs (1 × 105 cells per tube) were included in the
experiment for calibrating the flow cytometer and setting up a baseline for gating and
data analysis (unstained – no antibody and single-stain – BM-MSCs or SMCs positively
stained with one antibody of interest). The cell suspension was then centrifuged (10000 ×
g, 15 seconds) and the supernatant aspirated. The cell pellet was washed by gently mixing
the cell suspension in 800μL of FACS buffer containing 1× PBS, 25 mM HEPES
(Fisher), 1% w/v BSA, 0.02% w/v NaN3 and 0.5 mM EDTA (Amresco, Solon, OH). The
cell suspension was then re-centrifuged (10000 × g, 15 seconds) and the supernatant
removed. A cocktail of antibodies for BM-MSC surface markers (Table 3.5) exceeding
100 μL was prepared by diluting them in FACS buffer. BM-MSC control cell types as
well as BM-MSCs differentiated with an without growth factors were incubated (25 °C,
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15 minutes, in the dark) with the surface antibody cocktail. The cells were washed twice
with 800 μL of FACS buffer and centrifuged (10000 × g, 15 seconds) and the supernatant
aspirated.
Cell Type and
Test condition

CD 29
(µL)

CD 90
(µL)

aSMA
(µL)

SM22-α
(µL)

SMMHC
(µL)

FACS
buffer
(µL)

Perm
buffer
(µL)

0

0

0

0

0

80

0

1

0

0

0

0

79

0

0

1

0

0

0

79

0

0

0

0

0

0

0

80

0

0

2.5

0

0

0

77.5

0

0

0

1.28

0

0

78.72

SMC
SMMHC

0

0

0

0

1.25

0

78.75

BM-MSCs

1

1

2.5

1.28

1.25

78

74.97

SMC

1

1

2.5

1.28

1.25

78

74.97

BM-MSCs + NF

1

1

2.5

1.28

1.25

78

74.97

BM-MSCs
unstained
BM-MSCs
CD 29
BM-MSCs
CD 90
SMCs
unstained
SMC
αSMA
SMC
SM22-α

BM-MSCs +
1
1
2.5
1.28
1.25
78
74.97
PDGF-BB
BM-MSCs + TGF1
1
2.5
1.28
1.25
78
74.97
β1
Table 3.5 Summary of unstained, single stain and test samples including buffer volumes and antibodies.

In order to stain for SMC specific intracellular proteins, SMCs and BM-MSCs
differentiated with and without growth factors cell pellets were then suspended in 100 μL
of IC Fixation buffer (eBioscience, San Diego, CA) and incubated (25 °C, 20 minutes, in
the dark). Meanwhile, to prepare an intracellular antibody cocktail (Table 3.5), the SMC
specific antibodies were diluted in 1× permeabilization buffer (eBioscience, San Diego,
CA) to a total volume (antibody + buffer) less than 100 µL. Fixed cell pellets were
permeabilized by mixing with 1 × permeabilization buffer (150 µL), the cell suspension
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centrifuged to re-pellet cells and supernatant aspirated. Cell pellets were re-suspensed in
1× permeabilization buffer (150 µL) and re-centrifuged and supernatant aspirated. The
resulting cell pellets were incubated (25 °C, 15 minutes, in the dark) with the intracellular
antibody cocktail. The antibody cocktail was diluted with 1 × permeabilization buffer
(150 µL), re-centrifuged and supernatant aspirated. Cells were washed with 150 µL of
each 1 × permeabilization buffer (2 cycles) and FACS buffer (2 cycles). The cells
suspensions were re-centrifuged, re-suspended in FACS buffer (150 µL) and filtered with
a polystyrene tube with 40 µm cell strainer cap. Ms. Cathy Shemo from the Flow Core at
The Lerner Research Institute then analyzed the samples with a flow cytometer.
	
  
Gating and analysis. Data collected from the flow cytometer was analyzed using a
software package called FlowJo®. Based on the unstained and single-stain control data,
gating for each antibody was performed on the experimental data. Gating is a process of
eliminating results from unwanted particles (dead cells, debris) and selectively visualize
cells of interest. A single parameter histogram was plotted to highlight the relative
fluorescence intensity (x-axis) against the number of events (cells, y-axis) for each
antibody by Ms. Anne Cotleur from the Flow Core at The Lerner Research Institute.
3.4 Cell cycle analysis
Cell cycle profiles of BM-MSCs, BM-MSCs derived cell populations (in the
presence and absence of growth factors), and SMCs were compared to confirm that
differentiation culture protocols indeed generated SMC-like cells and to compare
differentiation outcomes between 7 and 14 day time points. The cell lines were trypsinzed
at 80% confluence and enucleated by suspending in a buffer containing detergent (NP-

55

40), RNAse, and Propidium iodide (PI; Vindelov’s reagent; Invitrogen). After incubation  
for two hours, cell cycle analysis of the cell layers were generated using Accuri® C6 flow
cytometer (BD Biosciences) and further comparative analysis was performed using  
FCSExpress® analysis software (De Novo Software, Los Angeles, CA).
3.5 RT-PCR for gene expression changes
Cell culture. BM-MSCs cells differentiated with and without factors for 7 and 14 days,
BM-MSCs and SMC cultured for 7 and 14 days, were expanded for 7 days, then
trypsinized and seeded at a density of 3 × 104 cells per well of 6-well plates (area = 9.6
cm2). Medium A (for SMCs and differentiated BM-MSCs) or Medium B (for control type
BM-MSCs) was added to each well, and the respective cells were cultured for 21 days,
with medium changes every 3 days.

RNA isolation. After 21 days of culture, cells were harvested, and total RNA was
isolated using the RNeasy kit (Qiagen, Valencia, CA) at 25 °C. The cell layer was
disrupted from each 6-well plate by adding 600 μL of RLT buffer (a guanidine thymocyte
buffer) and 600 μL of 70% v/v RNase free ethanol, and scraping off. Each lysed sample
was homogenized by gentle mixing with a micropipette and transferred to an RNeasy
column. The RNeasy column was centrifuged (3 cycles, 8000 × g, 15 seconds, 25 °C)
with RLT buffer (600 µL), RW1 buffer (700 μL) and RPE buffer (500 μL) added
respectively prior to each centrifugation cycle and the flow-through discarded. The
RNeasy column was centrifuged at the highest possible speed for 1 minute and then
moved to a new 1.5 mL tube. RNase free water (30 μL) was added and re-centrifuged
(8000 × g, 1 minute).
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RNA quantification. The isolated RNA was quantified using a Quanti-iTTM RiboGreen©
RNA Reagent Kit (Invitrogen), an ultrasensitive fluorescent nucleic acid stain for
quantifying RNA in solution. TE Buffer (1×; 10 mM Tris-HCL, 1 mM EDTA, pH 7.5)
prepared in nuclease-free water was used to dilute the RiboGreen© reagent, RNA
standard stock solution and RNA isolated from test cell cultures. The RiboGreen© reagent
was warmed (25 °C) and an aqueous working solution was prepared by diluting dye stock
in 1× TE buffer to prepare a dilution of 1:200. To generate an RNA standard curve, a 2
μg/mL stock solution was prepared by diluting 20 μL of RNA stock (100 μg/mL) in 980
μL of 1× TE buffer (a dilution of 1:50). The standard stock solution (200 μL) was
pipetted into a 96-well plate in duplicates and serially diluted by adding 1× TE buffer
(100 μL). For the experimental samples, 2 μL of RNA isolate was diluted in 98 μL of 1×
TE buffer and added to the same 96 well plate in duplicates. Diluted RiboGreen© dye
(100 μL) was added to all wells containing RNA sample or RNA stock solutions. The
sample fluorescence was measured using a spectrofluorometer set for λexcitation = 488 nm
and λemission = 525 nm. The volumes of the sample RNA solutions were adjusted such that
a target amount of 1000 ng of RNA per sample was obtained. In addition to the volumes
of RNA, volumes of nuclease free water were calculated to achieve a total volume of 15
μL of RNA plus water for complementary DNA (cDNA) reverse transcription.

cDNA transcription and isolation. cDNA from the RNA elute was isolated and extracted
using iScript™ cDNA synthesis kit (Bio-rad, Hercules, CA) that contains three
components: a reaction mix with deoxyribonucleotides and hexamers that serve as
primers, reverse transcriptase enzyme and nuclease free water. To prepare 20 μL of
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cDNA per experimental sample, 15 µL of RNA isolate, 4 µL of reaction mix and 1 µL of
reverse transcriptase enzyme were mixed together in a nuclease-free PCR plate. The PCR
plate was incubated in a thermocycler set at different temperatures for several periods to
assist the reactions in producing cDNA (25 °C, 5 minutes; 42 °C, 30 minutes; 85 °C, 5
minutes and held at 4 °C). The cDNA samples were diluted 3 times with nuclease free
water stored at -20°C.

RT-PCR sample preparation and reaction. Gene expression was quantified by a real
time polymerase reaction performed in an ABI PRISM 7000 system (Applied
Biosystems, Foster City, CA) using SYBR® green master mix (Applied Biosystems) and
primer sets previously optimized in our lab for SMCs. PRC plates for genes encoding for
αSMA, Caldesmon, SMMHC, tropoelastin, LOX and 18S (housekeeping gene), were
prepared for amplification. The reaction mix was prepared such that a total volume of 20
μL was not exceeded (10 µL of 2× SYBR® green master mix, 3 µL of cDNA, 2 µL of
primer and 5 µL of nuclease-free water) in triplicates. Two controls – no template control
(0 µL of cDNA, 8 µL of nuclease-free water) and RNA control (3 µL of RNA, 5 µL of
nuclease-free water) was also prepared in triplicates.

Data analysis. RT-PCR data was analyzed using the 2-ΔΔCT method, a relative
quantification technique that describes the change in the expression of a target gene
relative to a control. CT stands for the threshold cycle and indicates the partial cycle
number at which the amount of amplified gene reaches the fixed threshold. The CT values
generated by the RT-PCR machine were then analyzed by the 2-ΔΔCT method51. RT-PCR
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for 18S, a housekeeping gene was performed and was used to normalize all CT values
obtained for the genes in question per treatment condition giving the ΔCT value. The ΔCT
values were averaged and subtracted from ΔCT values of SMCs (positive control) to give
the ΔΔCT value. To obtain the fold change, the ΔΔCT value was multiplied by -1 and was
used as the exponent of 2 to give the 2-ΔΔCT values.
3.6 DNA assay for cell proliferation
Cell culture and harvest. BM-MSCs differentiated with and without factors for 7 and 14
days, BM-MSCs and SMCs cultured for 7 and 14 days were expanded further for days,
then trypsinized and seeded at a density of 3 × 104 cells per well of 6-well plates (area =
9.6 cm2). Medium A (for SMCs and differentiated BM-MSCs) or Medium B was added to
each well. The cells were cultured for 21 days with medium changes every 3 days and
harvested in 3mL Pi Buffer (50 mM Na2HPO4, 2 mM EDTA, 0.02% w/v NaN3). The cell
suspensions were sonicated on ice and 300 μL was aliquoted for DNA assay and the
remaining 2.7 mL was stored (-20 °C) for fastin and hydroxyproline assay.

Sample preparation. Calf thymus DNA stock solution (100 μg/mL) was diluted in
NaCl/Pi buffer (4 M NaCl, 50 mM Na2HPO4, 2 mM EDTA, 0.02% NaN3) tenfold and
used to obtain a standard curve. In an opaque 96-well plate, 200 μL of DNA stock
solution was added to duplicate wells and serially diluted in Pi buffer using a multichannel pipette. To other wells of the 96-well plate, 98 μL of Pi buffer and 2 μL of test
cell culture DNA was added. Bisbenzimide (Hoechst 33258; Invitrogen) dye stock
solution (0.2 mg/mL) was diluted (1:100) in NaCl/Pi buffer. The diluted dye solution
(100 µL) was distributed to wells with samples, incubated (25 °C, 30 minutes, in the
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dark) and the sample fluorescence was measured using a spectrofluorometer set for
λexcitation = 356 nm and λemission = 525 nm. The cell density in test and treatment cell layers
was calculated based on an estimate of 6 pg DNA/cell52.
3.7 Fastin assay for elastin quantification
Sample preparation. The amounts of matrix elastin (alkali-soluble and insoluble
fractions) were quantified using a Fastin assay (Biocolor Ltd. Carrickfergus, County
Antrim, UK). The sonicated cell culture samples stored in -20 °C (section 3.6) were
thawed (37 °C) and divided into two tubes for each treatment condition (800 μL per
tube). An equal volume of 0.1 M NaOH was added to the cell suspension and heated for
1 hour. Each sample was then centrifuged (12000 rpm, 10 minutes) and the supernatant
divided equally – one aliquot for the hydroxyproline assay and one for the Fastin assay
for soluble elastin. The supernatants and cell pellets were stored at -20 °C for further
biochemical processing.
The cell pellets were thawed, mixed with 0.25 M oxalic acid (250 μL), heated for
1 hour, centrifuged (12000 rpm, 10 minutes), the supernatant transferred to centrifugal
filter columns which were centrifuged (12000 rpm, 10 minutes) and the flow-through
discarded. Insoluble elastin was released into collection tubes by centrifuging (8000 rpm,
15 seconds) inverted filter columns into new tubes and further diluted using 0.25 M
oxalic acid (200 μL).

Alkali-soluble and insoluble elastin assay. The assay was performed on duplicate test
samples, elastin standards and reagent blanks. Elastin standards (0, 12.5, 25, 50	
   and	
   100	
  
μL) mixed with 0.25 M oxalic acid (total volume per standard = 100 μL) were prepared.
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Elastin from all the samples (cell pellets, supernatants, standards) was recovered
by the addition of equal volume of elastin precipitating reagent (Biocolor Ltd.
Carrickfergus, County Antrim, UK), incubation (25 °C, 10 minutes), concentration of
precipitate by centrifugation (10000 × g, 10 minutes) and discarding the supernatant. Any
remaining fluid was removed by forceful tapping onto absorbent paper towels and water
droplets removed with a Q-tip. Samples were then incubated (25 °C, 90 minutes) with
Fastin dye reagent (500 μL; Biocolor Ltd.) while simultaneously being vortexed and
mechanically mixed to bring the sample precipitate into solution. The resulting insoluble
elastin-dye complex (due to ammonium sulfate in the dye reagent) was separated from
unbound dye by centrifugation (10000 × g, 10 minutes) and the supernatants discarded.
Any remaining fluid was removed by forceful tapping onto absorbent paper towels and
water droplets removed with a Q-tip. The elastin-dye complex was brought into solution
by adding a dye dissociation reagent (250 μL; Biocolor Ltd.) and briefly mixing the
contents with a vortex mixer. Samples were then transferred into an opaque 96-well plate
and the absorbance measured using a spectrofluorometer set for λabsorbance = 513 nm. The
measured elastin amounts were normalized to corresponding DNA amounts to provide a
reliable basis of comparison between samples.
3.8 Hydroxyproline assay for collagen quantification
Sample preparation. A Hydroxy-proline (OH-Pro) assay was used to estimate collagen
content within BM-MSC cultures differentiated with and without growth factors for 7 and
14 days, SMC and BM-MSC controls. The samples (digestates from section 3.7) were
hydrolyzed in duplicates (115 °C, 16 hours) with 6 N HCl (800 μL) per test condition and
then cooled (25 °C).
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Determination of OH-Pro content. The samples were then placed in a heater block (37
°C) in two batches and HCl evaporated under a stream of nitrogen directed into each via a
silicone capillary tubing. Each hydrolyzate dissolved in de-ionized water (100 μL) as
well as collagen standard solutions (0, 10, 25, 50, 100, 150, 300 μg/mL) were placed into
duplicate glass tubes (40 μL of sample per tube). The samples and standards were
vortexed with Chloramine-T reagent (250 μL), incubated (25 °C, 20 minutes), briefly
vortexed and incubated (60 °C, 15 minutes) again with Perchloric acid (250 μL). The
samples were aliquoted into duplicate wells of an opaque 96-well plate (250 µL) after a
final vortexing and the absorbance measured using a spectrofluorometer set for λabsorbance
= 558 nm. The matrix collagen amounts in the samples were calculated based on the
coefficients obtained from the standard curve, and normalized to DNA content of
corresponding cell layers.
3.9 LOX activity assay
Sample preparation. Lysyl oxidase (LOX) is an endogenous enzyme that crosslinks
tropoelastin, thereby making it insoluble. Estimating the activity of this enzyme in the
ECM and therefore culture medium is an indirect measure of cell-mediated crosslinking
of elastin within cell layers to form mature matrices. Therefore, spent culture medium
aliquots from the 21-day cell culture period of BM-MSCs differentiated with and without
growth factors for 7 and 14 days, SMC and BM-MSC control cultures were collected and
pooled during each medium change stored at -20 °C prior to the LOX activity assay.
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Determining LOX protein synthesis. The media samples were assayed for LOX activity
using a flurometric assay (Amplex® Red Assay, Molecular Probes, Eugene, OR) based on
measurement of H2O2 released when LOX oxidatively deaminates alkyl monoamines and
diamines52. Briefly, two buffers were prepared with the reaction buffer (1×) provided by
the assay – 1) horseradish peroxidase (HRP) solution (0.2 U/mL), 2) 1.2 M urea, 10 mM
diaminopentane and HRP (50 μL). The Amplex® Red dye was reconstituted (10 mM)
with DMSO (60 μL) of DMSO and added to the buffers. Peroxide standards (0,10, 20,
30, 40, and 50 μL) were prepared according to the manufacturer’s protocol. To an opaque
96-well plate, peroxide standards and media samples were added with buffers such that
the total volume per well equal 100 μL. Additionally, to half of the media sample wells
the buffer with diaminopentane and to the others, buffer no diaminopentane was added.
The plate was incubated (37 °C, 30 minutes) and the absorbance measured using a
spectrofluorometer set for λabsorbance = 560 nm. Amounts of peroxide were calculated
based on the coefficients obtained from the standard curve.
3.10 Statistical analysis
Comparisons between the BM-MSCs differentiated in the presence and absence
of growth factors, BM-MSCs, and SMCs were analyzed using the Student’s t-test.
Statistical significance was deemed for p < 0.05. Data are shown as mean with ± standard
error with symbols in figures denoting statistical significance (p < 0.05) for groups
compared with SMCs, BM-MSCs, and BM-MSCs differentiated without the presence of
exogenous cytokines.
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CHAPTER IV
RESULTS AND DISCUSSION

4.1 Introduction
The following sections of this chapter presents the results obtained from various
experiments conducted to first demonstrate the impact of growth factor choice and time
period of differentiation on BM-MSCs in their transformation into SMCs. The
experiments also assess the quantity and quantity of elastin produced by BM-MSCderived SMCs in the presence and absence of growth factors when compared to
terminally differentiated adult vascular SMCs (positive controls) and undifferentiated
BM-MSCs (negative control). The materials and methods used to conduct the
experiments are detailed in Chapter III of this thesis.
4.2 Immunofluorescence
BM-MSCs were differentiated in the presence of growth factors (TGF-β1 and
PDGF-BB) or in their absence (no factors – NF) on tissue culture plastic coated with
hFN. The control cell types SMCs and BM-MSCs, however, were cultured on uncoated
tissue culture plastic. Therefore, qualitative and quantitative data on cell expression of

64

cell type specific phenotypic markers obtained via immunofluorescence (IF) was only
compared among BM-MSCs treated with TGF-β1, PDGF-BB and no growth factors.
Data obtained from labeling SMCs is presented in this section to demonstrate outcomes
sought to be achieved by differentiating BM-MSCs and to serve as a	
   point of comparison
for discussion purposes. Results from staining for three of the tested four SMC-specific
phenotypic markers (αSMA, Calponin and SM22-α) are shown in this section for NF,
TGF-β1, and PDGF-BB treated BM-MSCs. In all cases, BM-MSC-derived cells did not
express SMMHC, a late-stage SMC marker, and hence are not shown.
Qualitative results. Figures 4.1 through 4.4 show qualitatively the average staining per
culture for each experimental condition demonstrating the positive effects of the three
growth factors in coaxing differentiation of BM-MSCs towards an SMC phenotype. BMMSCs cultured for 7 and 14 days on a non-fibronectin coated substrate did not show
positive staining for any of the SMC-specific phenotypic markers (data not shown).
Figure 4.1 shows the staining of SMCs with α-SMA, Calponin and SM22-α. Figure 4.2
shows a comparison between NF, PDGF-BB and TGF-β1 treated BM-MSCs for staining
with α-SMA, Figure 4.3 shows a comparison between NF, PDGF-BB and TGF-β1 for
staining with Calponin and Figure 4.4 shows a comparison between NF, PDGF-BB and
TGF-β1 for staining with SM22-α.
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14 d

SM22-α

Calponin

α-SMA

7d

Figure 4.1. Fluorescence images at 10× magnification showing staining of SMCs for α-SMA, Calponin
and SM22-α (red) following 7 and 14 days of culture on uncoated substrates. DAPI-stained nuclei appear
blue.
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14 d

NF

7d

TGF-β1

PDGF-BB

A.

Figure 4.2. Fluorescence images at 40× magnification showing αSMA staining (red) of BM-MSCs
differentiated with and without growth factors over 7 and 14 days. DAPI-stained nuclei appear blue.

In Figure 4.2, BM-MSCs differentiated with PDGF-BB and TGF-β1 for 7 and 14
days show positive staining for α-SMA, a conclusive early stage marker of SMCs,
compared to those with no growth factors, which showed negative staining. These results
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indicate that the growth factors are essential to coaxing BM-MSCs toward a SMC-like
phonotype in vitro culture.

14 d

TGF-β1

PDGF-BB

NF

7d

Figure 4.3. Fluorescence images at 40× of BM-MSCs differentiated with and without growth factors over 7
and 14 days stained with Calponin (red), a mid-stage SMC phenotypic marker. DAPI-stained nuclei appear
in blue.
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As seen in figure 4.3, BM-MSCs differentiated with PDGF-BB and TGF-β1
show positive staining for Calponin, a mid-stage SMC marker, while BM-MSCs cultured
for 7 days on hFN substrates in the absence of any growth factors stained negatively for
Calponin. While this suggests that the growth factors are essential to differentiate BMMSCs into SMC-like cells, the positive staining of 14 day differentiated BM-MSCs (NF)
for Calponin additionally suggests that the hFN substrate itself is able to coax some
degree of differentiation of the BM-MSCs although this occurs at more extended culture
times. These results indicate that the growth factors as well as substrate (hFN) influenced
BM-MSCs differentiation toward a SMCs-like phonotype in vitro.
In Figure 4.4 different results are observed. Both BM-MSCs cultured on hFN
substrates with no factors and those differentiated on the same substrate but with TGF-β1
over 7 days showed little/no staining. In the case of TGF-β1, the staining appears highly
diffused and may likely be due to non-specific binding of the primary antibody. At 14
days of differentiation, the results were different, in that both the NF and growth factor
treated cultures stained positive for SM22-α though the TGF-β1 treated BM-MSCs
appeared to have more intense staining. Treatments with PDGF-BB and no factors have
relatively less intense staining. A greater number of cells appear to stain positive for
SM22-α in the image with no factor treated BM-MSCs. Thus, while PDGF-BB coaxes
early expression of SM22-α, the expression levels appear unchanged with increase in
differentiation time. Together, these results again, suggest a combinatory effect of
substrate as well as growth factor-induced BM-MSC differentiation toward a SMC-like
phonotype in vitro.
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14 d

TGF-β1

PDGF-BB

NF

7d

Figure 4.4. Fluorescence images at 40× of BM-MSCs differentiated with and without growth factors for 7
and 14 days, and then stained with SM22-α (red). DAPI-labeled nuclie appear blue.

Quantitative results. The density/intensity parameter summates the density or intensity of
fluorescence inside each ‘object’ (cell). Figure 4.5 shows the average density or intensity
of staining normalized to the total nuclei count obtained in the FOV. The percent area is

70

the ratio of the average area stained (µm2) to the total area (µm2) in the FOV. This ratio
normalized to the total cell count in the FOV is shown in Figure 4.6.

Staining intensity per cell
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6.0E+06
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0.0E+00
NF 7d

NF 14 d

aSMA

PDGF-BB PDGF-BB TGF-b1 7d
7d
14d

Calponin

TGF-b1
14d

SM22a

Figure 4.5. Average SMC phenotypic marker staining intensity in BM-MSC cultures differentiated with
NF, PDGF-BB and TGF-β1 shown normalized to the number of nuclei in FOV.

From Figure 4.5, we deduce that a) in the absence of growth factors, no
differentiation is initiated at least for 7 days, b) a hFN substrate alone is able to coax
differentiation to a SMC-like phenotype but only at a possible minimum of 14 days of
culture, and c) the differentiated cells are highly contractile in expressing the SMC
marker, SM-22α intensely. The results are not surprising since the basal medium used to
culture the cells contain low levels of PDGF-BB (Section 3.1). The data also suggests
that d) additional PDGF-BB provided to supplement basal levels in the serum, does
hasten early (7 day) differentiation to an SMC phenotype compared to NF conditions,
although the cells appear to lose this contractile phenotype at longer periods of
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differentiation (i.e., 14 day). Differently, while TGF-β1, like PDGF-BB, provides early
stimulus to BM-MSCs toward differentiation into SMC-like cells, the SMC-like
characteristics of the derived cells are enhanced with differentiation time in that
expression of both Calponin and its homologue SM22-α are progressively increased. An
interesting observation was the low levels of α-SMA expression by the BM-MSC-derived
cells, regardless of substrate presence or absence of growth factors, identity of growth
factors and differentiation time. Studies have shown that non-vascular SMCs
predominantly express γ-actin and not α-actin, which is expressed mostly by vascular
SMCs53. Thus it is possible that our differentiation protocols yield cells that more closely
resemble non-vascular SMC types.

Percent area staining per cell

4.5E-02
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NF 14 d
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PDGF-BB PDGF-BB TGF-b1 7d
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Calponin

TGF-b1
14d

SM22a

Figure 4.6. Average fractional area of cell fluorescing due to expressed SMC markers, normalized to the
number of differentiated BM-MSC nuclei in the FOV. The BM-MSCs were differentiated with NF, PDGFBB and TGF-β1 over 7 and 14 days.
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As seen in Figure 4.6, there is no difference among the treatment conditions for
average

percent

area

of

α-SMA

staining

per

cell,

which

is

low

across

treatments/differentiation times. When expressed in terms of fluorescing cell area, trends
in expression of the SMC markers were maintained between treatments, differentiation
times, as deduced from Figure 4.5. The area of staining was twice as more in the TGF-β1
and NF treated BM-MSCs for 14 days compared to the PDGF-BB treated group for the
same period. Irrespective of treatment group/time, (except for NF for 7 days), the derived
cells showed greatest expression of SM22-α. The data presented in this manner again
agree with the inferences made from Figure 4.5.
The results of quantitative analysis of immunofluorescence data suggest that hFN
itself may be a good modulator of SMCs-like phenotype. Also, since the culture medium
for NF treated BM-MSCs contained a basal amount of PDGF-BB, the data demonstrates
the influence of basal cytokine levels in the serum in the differentiation process.
Regardless, our results also indicate that TGF-β1 stimulates earlier differentiation of BMMSCs into SMCs, and that these differentiation effects, unlike that induced by PDGFBB, are enhanced with duration of differentiation.
4.3 Flow cytometry
Flow cytometry results for BM-MSCs differentiated with NF, PDGF-BB and
TGF-β1 shown as histograms with expression intensities overlaid for comparison
between treatment groups (Figure 4.7).
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SM22-α
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PDGF-BB
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Figure 4.7. Comparison of the distribution of fluorescence intensities for α-SMA, SMMHC and SM22-α,
among BM-MSCs differentiated with NF, PDGF-BB and TGF-β1 for 7 and14 days column.

Flow cytometry indicates that BM-MSCs differentiated with TGF-β1, especially
for 14 days, more intensely express α-SMA than do BM-MSCs differentiated with TGFβ1 over 7 days, BM-MSC cultured with no factors, or those differentiated with PDGFBB. There was no difference in expression of other later-stage SMC-specific phenotypic
marker proteins (SMMHC, SM22-α) between the treatment conditions, suggesting
(especially with SMMHC) that terminal differentiation was not approached.
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4.4 Cell cycle analysis
Cell cycle analysis profiles for SMCs, BM-MSCs, and BM-MSCs differentiated
with NF, PDGF-BB and TGF-β1 over 7 and 14 days, were normalized to the peak values
within the sample and compared. Figure 4.8 shows the comparison of cell cycles and
Table 4.1 and 4.2 show the percentage of cells in different phases of the cell cycle.
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Figure 4.8. Cell cycle profiles across SMCs , BM-MSCs and BM-MSCs differentiated with NF, PDGF-BB
and TGF-β1 for (A) 7 days (B) 14 days. Legend: RMSC = BM-MSCs, TGFb = BM-MSCs + TGFβ1,
PDGF = BM-MSCs + PDGF-BB, No GF = BM-MSCs + NF, ASMC = SMCs.

Cell lines

sub G1

G1

S

G2

SMC

9.49

86.15

2.54

1.82

BM-MSC

0.86

44.09

38.2

16.85

BM-MSC + NF

1.66

51.59

34.32

12.43

BM-MSC + PDGF-BB

1.68

44.5

39.35

14.47

2

52.3

32.45

13.25

BM-MSC + TGF-β1

	
  
Table 4.1: Percent gated single cells in different phases of cell cycle observed in SMC, BM-MSCs and
BM-MSCs differentiated for 7 days in the presence and absence of growth factors.

Cell lines

sub G

G

1

1

S

G

2

SMC

14.01

72.78

10.31

2.9

BM-MSCs

0.75

53.14

32.08

14.03
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Cell lines

sub G

G

1

1

S

G

2

BM-MSCs + NF

11.7

48.02

26.54

13.74

BM-MSCs + PDGF-BB

3.45

45.97

36.95

13.63

BM-MSCs + TGF-β1

9.71

58.05

22.17

10.07

Table 4.2: Percent gated single cells in different phases of cell cycle observed in SMC, BM-MSCs and
BM-MSCs differentiated for 14 days in the presence and absence of growth factors.

When the results in Tables 4.1 and 4.2 are compared, they show that a hFNcoated substrate has no significant effect on mitotic activity of BM-MSCs and those
differentiated with TGF-β1 exhibit a greater number of cells collectively in the sub G1
and G1 phase of the cell cycle (suggestive of lower mitotic activity and likely
differentiated characteristics) compared to PDF-BB or NF treatment. Most SMCs were in
the sub G1/G1 phase, suggestive of a differentiated state. Longer differentiation time
results in a lower percentage of cells in the G2, M and S phases.
4.5 RNA quantification and RT-PCR
RNA quantification. RNA isolated using the Qiagen kit was quantified using the
RiboGreen® RNA quantification reagent and kit in order to reverse transcribe known
amounts of RNA into DNA for the polymerase chain reaction. Since RNA from the 7 day
and 14 day differentiation cultures were reverse transcribed on different days, two
standard curves were obtained. The first standard curve corresponds to the absorbances
obtained for 7 day differentiation RNA samples (Figure 4.9) and the second standard
curve corresponds to absorbances obtained for 14 day differentiation RNA samples
(Figure 4.10). Absorbance data from six biological replicates per differentiation
condition, loaded in duplicates were obtained. The absorbance values were averaged and
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the average RNA in microgram per microliter were calculated using the slope and
intercept obtained from the respective standard curves. This value was multiplied by a
dilution factor of 50 to account for the dilutions when samples were prepared for
quantification. Since there were variations in the concentration of RNA among the
samples, a known quantity of RNA (1000 ng) was chosen so that the same amounts of
RNA were reverse transcribed for PCR. The concentration of RNA was divided by 1000
ng to obtain volumes for each biological replicate (Table 4.3).
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Figure 4.9. Standard curve obtained from the RNA quantification for 7 day differentiation samples.

6000
y = 234.74x + 407.65
R2 = 0.8903

Absorbance

5000
4000
3000
2000
1000
0
0

5

10
15
RNA concentration (ug/mL)

20

25

Figure 4.10. Standard curve obtained from RNA quantification for 14 day differentiation samples.
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7 day

Sample

RNA (µL)
required

14 day

Water (µL)
Water (µL)
RNA (µL)
(total 15
(total 15
required
µL)
µL)

1.18
13.82
MSC_1
1.31
13.69
1.16
13.84
MSC_2
1.44
13.56
1.17
13.83
MSC_3
2.79
12.21
1.16
13.84
MSC_4
1.78
13.22
1.31
13.69
MSC_5
1.56
13.44
1.44
13.56
MSC_6
1.72
13.28
4.16
10.84
SMC_1
1.93
13.07
1.92
13.08
SMC_2
2.74
12.26
2.38
12.62
SMC_3
2.54
12.46
2.32
12.68
SMC_4
2.75
12.25
1.80
13.20
SMC_5
2.40
12.60
2.64
12.36
SMC_6
2.57
12.43
1.36
13.64
NF_1
1.30
13.70
1.13
13.87
NF_2
1.05
13.95
1.72
13.28
NF_3
1.54
13.46
1.42
13.58
NF_4
1.74
13.26
1.65
13.35
NF_5
1.34
13.66
1.05
13.95
NF_6
1.27
13.73
2.18
12.82
P_1
1.21
13.79
1.34
13.66
P_2
1.96
13.04
1.40
13.60
P_3
1.21
13.79
1.34
13.66
P_4
1.54
13.46
1.10
13.90
P_5
15.00
0.00
1.27
13.73
P_6
1.24
13.76
14.60
0.40
T_1
2.12
12.88
2.20
12.80
T_2
2.61
12.39
2.01
12.99
T_3
5.11
9.89
2.29
12.71
T_4
9.16
5.84
1.73
13.27
T_5
1.73
13.27
1.68
13.32
T_6
1.80
13.20
Table 4.3. Tables with the volumes of RNA used per treatment condition and time period for PCR.
Legend: MSC = BM-MSCs, SMCs = SMC, NF = BM-MSCs + NF, P = BM-MSCs + PDGF-BB, T = BMMSCs + TGF-β1.

RT-PCR. Treatment-specific expression of three SMC phenotypic protein genes –
αSMA, Caldesmon and SMMHC and two genes encoding for elastic matrix/assembly –
elastin and LOX (elastin crosslinking enzyme) were investigated via RT-PCR. The data
obtained were analyzed using the 2-ΔΔ CT approximation method51. Statistical analysis for
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PCR data was done using an analysis of variance (ANOVA) to determine overall
significance in the data. The Tukey HSD and Fisher LSD multiple comparisons were
used to determined findings that were significant when comparing treatment groups.
Differences in α-SMA gene expression data for SMC cultured at 7 days versus 14
days (Figure 4.11) were statistically significant with those cultured for 14 days
expressing this contractile protein at four times the levels of those cultured for 7 days.
This finding is not surprising given that SMCs cultured for 14 days had twice the time
over which time, they likely generated matrix, a microenvironment which enhanced their
expression of contractile SMC marker proteins.

Fold Increase in gene expression
(log10 scale)

10.0
*

1.0

0.1
7d

14 d

Figure 4.11. Fold differences in gene expression of αSMA (± standard error) in SMC cultured for 7 and 14
days. * designates data at different time points per treatment with 95% confidence level.

PCR data with multiple comparisons for αSMA gene expression normalized to
gene expression data in SMCs is shown in Figure 4.12 and Table 4.4 lists groups that
differ with p-values < 0.05. Compared to SMCs cultured for 7 days, α-SMA expression
by BM-MSCs, BM-MSCs treated with PDGF-BB and BM-MSCs treated with TGF-β1
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were statistically less (p-values < 0.05 listed in Table 4.4). At 7 days of differentiation,
BM-MSCs treated with and with out growth factors expressed α-SMA at significantly
higher levels than BM-MSCs alone. When comparing the 7 day differentiation groups,
BM-MSCs differentiated with TGF-β1 have significantly higher gene expression
compared with those with PDGF-BB or without cytokines. Whereas, at 14 days of
differentiation α-SMA gene expression in cultures of BM-MSCs treated with growth
factors (both PDGF-BB and TGF-β1) was statistically different from BM-MSCs cultured
with no growth factors. Between the two growth factors used at 14 days of
differentiation, BM-MSCs differentiated with TGF-β1 have higher gene expression than
PDGF-BB treated cells. Interestingly, BM-MSCs cultured on hFN substrates with NF
over 14 days expressed α-SMA mRNA at levels that exceeded that expressed by SMCs,
indicating that it is a strong determinant of BM-MSC differentiation into SMCs. The fact
that growth factor treated BM-MSCs at 14 days show less expression of α-SMA mRNA
relative to the NF case, indicates that growth factor can also modulate in these cases,
tandem with the hFN substrate, reduce α-SMA mRNA expression.
The effect of culture period (BM-MSCs and SMCs) and differentiation periods
(BM-MSCs treated with NF, PDGF-BB and TGF-β1) provided statistically significant
data designated by ‘*’ for p < 0.05 in Figure 4.12. BM-MSCs cultured for 14 days have
greater gene expression of αSMA than those cultured for 7 days. This suggests that in
prolonged culture even on uncoated substrates, BM-MSCs can auto differentiate at least
partially, to enhance their expression of αSMA. However, BM-MSCs show greater
expression of this gene when differentiated in the presence of PDGF-BB for 7 days when
compared to 14 days.
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Fold Increase in gene expression
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Figure 4.12. Fold differences in gene expression of αSMA (± standard error) for BM-MSC differentiated
with or without growth factors for 7 and 14 days normalized to SMC gene expression. Legend: MSC =
BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = BMMSCs + TGF-β1. * designates data at different time points per treatment with 95% confidence level.

Comparison
Group

Groups that
differ

SMC 7d

All 7d

< 0.05

MSC 7d

All 7d

< 0.05

NF 7d

TGFb1

0.003

PDGFbb 7d

TGFb1

0.000

SMC 14d

None

>0.05

MSC 14d

NF 14d

0.000

TGFb1 14d

0.016

PDGFbb 14d

0.000

TGFb1 14d

0.000

TGFb1 14d

0.036

NF 14d

PDGFbb 14d

p-value

Table 4.4. Post-Hoc comparison table with p-values indication significance in fold differences in gene
expression for αSMA for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs,
SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB
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Differences in Caldesmon gene expression data for SMCs cultured at 7 days
versus 14 days (data not shown) were not statistically significant indicating that longer
culture time has no effect on the gene expression of Caldesmon in SMCs.
PCR data with multiple comparisons for Caldesmon gene expression normalized
to gene expression in SMCs is shown in Figure 4.13. Gene expression levels for
Caldesmon in BM-MSCs differentiated for 7 days with PDGF-BB or TGF-β1 compared
to BM-MSCs or BM-MSCs treated without any growth factors showed no statistically
significant differences (Table 4.5), but appears to be less compared to SMCs. This
finding suggests that treatment of growth factors for 7 days does not have an effect on
Caldesmon gene expression, at least at the 7 day differentiation time point.
At 14 days of culture, BM-MSCs exhibited higher Caldesmon mRNA expression
levels compared to the 7 day culture group, indicating that the cells may autodifferentiate, developing more contractile characteristics. However, the gene expression
levels were still lower than that observed in SMCs at the same time. The caldesmon
mRNA expression levels in the NF group and TGF-β1 were no different from that in the
BM-MSC group, indicating lack of effect of hFN substrate and TGF-β1. PDGF-BB
appeared to enhance gene expression to levels seen in control SMC cultures compared to
those treated with TGF-β1. Data for 14 day cultures showed no statistically significant
differences using the Student’s t-test at the 95% confidence level (Table 4.5).
The effect of differentiation periods (BM-MSCs treated with NF and TGF-β1)
provided statistically significant data designated by ‘*’ for p < 0.05 in Figure 4.13. BMMSCs differentiated with NF and TGF-β1 for 14 days have greater gene expression of
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Caldesmon than those differentiated for 7 days. This suggests that in prolonged

Fold increase in gene expression

differentiation enhance their expression of Caldesmon.
10.0

*

1.0

*

0.1

0.0
MSC

SMC

NF

7day differentiation/culture

PDGFbb

TGFb1

14day differentiation/culture

Figure 4.13. Fold differences in gene expression of Caldesmon (± standard error) for BM-MSC
differentiated with or without growth factors for 7 and 14 days normalized to SMC gene expression.
Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB,
TGFb1 = BM-MSCs + TGF-β1. * designates data at different time points per treatment with 95%
confidence level.

Comparison
Group

Groups that
differ

p-value

SMC 7d

None

> 0.05

MSC 7d

None

> 0.05

NF 7d

None

> 0.05

SMC 14d

NF 14d

0.001

TGFb1 14d

0.000

MSC 14d

None

> 0.05

NF 14d

None

> 0.05

Table 4.5. Post-Hoc comparison table with p-values indication significance in fold differences in gene
expression for Caldesmon for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BMMSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB
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Differences in SMMHC gene expression data for SMCs cultured at 7 days versus
14 days (data not shown) were not statistically significant indicating that longer culture
time has no effect on the gene expression of SMMHC in SMCs.
PCR data with multiple comparisons for gene expression for the late-stage SMC
marker, SMMHC is shown in Figure 4.14. Compared to SMCs cultured for 7 and 14
days, differences in gene expression by BM-MSCs, BM-MSCs treated with NF and BMMSCs treated with PDGF-BB as well as TGF-β1 for SMMHC for the same time period
were significantly lower (p-values in Table 4.6). Neither the hFN substrate alone, or
together with either tested growth factor (PGDF-BB or TGF-β1), had any positive effect
on enhancing SMMHC gene expression in BM-MSCs treated for 7 days (Figure 4.14,

Fold increase in gene expression

Table 4.6).

10.0
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SMC
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TGFb1
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Figure 4.14. Fold differences in gene expression of SMMHC (± standard error) for BM-MSC
differentiated with or without growth factors for 7 and 14 days normalized to SMC gene expression.
Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB,
TGFb1 = BM-MSCs + TGF-β1. * designates data at different time points per treatment with 95%
confidence level.
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Comparison
group

Groups that
differ

p-value

SMC 7d

All 7d

< 0.05

MSC 7d

All 7d

< 0.05

SMC 14d

All 14d

<0.05

MSC 14d

SMCs 14d

0.005

TGFb1 7d

0.045

PDGFbb 14d

0.026

TGFb1 14d

0.016

NF 14d

Table 4.6. Post-Hoc comparison table with p-values indication significance in fold differences in gene
expression for SMMHC for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs,
SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB

Gene expression levels for SMMHC in 14 day cultures compared to 7 day
cultures appear to be higher in the case of BM-MSCs and BM-MSCs treated without any
growth factors suggesting a long culture period may enhance gene expression. Also, the
NF group at 14 days have significantly higher SMMHC expression levels compared to
either growth factor treated cultures. But, BM-MSCs treated with PDGF-BB and TGF-β1
at 14 day cultures appear to have lower gene expression levels for SMMHC compared to
7 day counterparts suggesting that growth factor treatment may reduce SMMHC gene
expression. However in, neither case, the differences are statistically significant (p-values
> 0.05). The TGF-β1 treated group for 7 days have significantly higher gene expression
than those differentiated for 14 days indicating that longer differentiation period with this
growth factor may decrease SMMHC expression.
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Differences in elastin gene expression data for SMCs cultured at 7 days versus 14
days (data not shown) were not statistically significant indicating that longer culture time
has no effect on the gene expression of elastin in SMCs.
Figure 4.15 shows treatment and cell type-specific differences in Elastin mRNA
expression. There was essentially no difference between undifferentiated BM-MSCs
cultured for 7 and 14 days on uncoated plastic; the expression levels remained much
lower than the terminally differentiated adult SMCs, whose expression also remained
unchanged between 7 and 14 days of culture. This confirms that undifferentiated BMMSCs are far less elastogenic than are SMCs. At the 7 days of attempted differentiation,
NF and PDGF-BB cultures had significantly lower Elastin gene expression than those
differentiated with TGF-β1, indicating that TGF-β1 positively enhances elastin gene

Fold increase in gene expression

expression (Table 4.7).
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Figure 4.15. Fold differences in gene expression of Elastin (± standard error) for BM-MSC differentiated
with or without growth factors for 7 and 14 days normalized to SMC gene expression. Legend: MSC =
BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = BMMSCs + TGF-β1. * designates data at different time points per treatment with 95% confidence level.
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Comparison
Group

Groups that
differ

p-value

SMC 7d

All

< 0.05

MSC 7d

NF 7d

0.005

TGFB1 7d

0.000

NF 7d

TGFb1 7d

0.001

PDGFbb 7d

TGFb1 7d

0.000

SMC 14d

MSC 14d

0.000

NF 14d

0.000

TGFb1 14d

0.000

NF 14d

None

> 0.05

Table 4.7. Post-Hoc comparison table with p-values indication significance in fold differences in gene
expression for Elastin for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs,
SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB

At the 14 days of attempted differentiation of the BM-MSCs in the presence of a
hFN-coated substrate alone (no factors), or together with PDGF-BB or TGF-β1,
expressed the elastin gene at statistically lower levels when compared to SMCs (Table
4.7) and in general, expression levels appeared consistently higher than the
undifferentiated BM-MSCs. Although BM-MSCs differentiated with growth factors
(PDGF-BB and TGF-β1) as well as no factors appear to be significantly higher in elastin
gene expression, data were not statistically significant indicating that longer
differentiation period may not enhance elastin gene expression, except in the case of NF
(7 versus 14 days).
Differences in lysyl oxidase (LOX) gene expression data for SMCs cultured at 7
days versus 14 days (data not shown) were not statistically significant indicating that
longer culture time has no effect on the gene expression of LOX in SMCs.
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Figure 4.16 shows treatment and cell type-specific differences in LOX mRNA
expression. There were statistical differences between undifferentiated BM-MSCs
cultured for 7 and 14 days on uncoated plastic but the expression levels remained much
lower than the terminally differentiated adult SMCs, whose expression also remained
unchanged between 7 and 14 days of culture. This confirms that undifferentiated BMMSCs produce far less amounts of LOX than SMCs. At the 7 days of attempted
differentiation of the BM-MSCs in the presence of a hFN-coated substrate alone (no
factors), or together with PDGF-BB or TGF-β1, did not result in any statistically

Fold increase in gene expression

significant increases (Table 4.8) in LOX gene expression.
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Figure 4.16. Fold differences in gene expression of LOX (± standard error) for BM-MSC differentiated
with or without growth factors for 7 and 14 days normalized to SMC gene expression. Legend: MSC =
BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = BMMSCs + TGF-β1. * designates data at different time points per treatment with 95% confidence level.

Comparison
Group

Groups that
differ

SMCs 7d

MSC 7d

0.000

NF 7d

0.000
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p-value

Comparison
Group

Groups that
differ
TGFb1 7d

MSC 7d

p-value
0.037

NF 7d

0.000

TGFb1 7d

0.002

NF 7d

None

> 0.05

SMCs 14d

None

> 0.05

MSC 14d

None

> 0.05

NF 14d

PGFbb 14d

0.048

TGFb1 14d

0.004

Table 4.8. Post-Hoc comparison table with p-values indication significance in fold differences in gene
expression for LOX for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs,
SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB

Gene expression for LOX in BM-MSC and BM-MSCs differentiated with and
without growth factors remained significantly lower than SMCs cultured for 14 days
(Table 4.8). At the 14 days of attempted differentiation of the BM-MSCs in the presence
of a hFN-coated substrate along with basal media (no factors) showed significantly
higher LOX gene expression when compared with PDGF-BB or TGF-β1 (Table 4.8).
Longer culture period for undifferentiated BM-MSCs notably enhances LOX gene
expression whereas for NF and TGF-β1 treated cultures, expression is reduced.
4.6 DNA assay for cell proliferation
DNA assay was performed at day 1 and day 28 of culture for each treatment
condition, and the positive (SMCs) and negative (undifferentiated BM-MSCs) cell types.
In general, as seen in Figures 4.17 and 4.18, proliferation of undifferentiated BMMSCs (subjected to 7 and 14 days of pre-culture) over 28 days was significantly higher
than that of likewise-cultured SMCs (significance values listed in Table 4.9 and Table
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4.10). The BM-MSCs that had been cultured for 14 days, thereafter proliferated more
slowly than did BM-MSCs that had been pre-cultured for 7 days, suggesting some degree
of auto-differentiation or at least phenotypic change with longer culture time.
Compared to the corresponding undifferentiated BM-MSC controls, BM-MSCs
cultured without any factors on hFN substrates, showed lower cell numbers after 28 days
of culture, with 14 day pre-cultured cells proliferating less than the 7-day pre-cultured
cells. This suggests that culture on hFN substrates drives some degree of
differentiation/phenotypic change in BM-MSCs and that longer periods of pre-culture
enhance such change. The apparent outcomes of culture on hFN substrates in absence of
differentiation-promoting growth factors agree well with that deduced from phenotypic
analysis of cells in Sections 4.2 and 4.5. When sought to be cultured with PDGF-BB over
7 days following expansion for 28 days, no significant differences were noted in cell
number (Figure 4.17) compared to the NF cultures although significantly higher cell
numbers were observed compared to TGF-β1 treated cultures confirming the mitogenic
nature of PDGF-BB. During the 14 day differentiation of BM-MSCs with TGF-β1, cell
numbers were significantly lower than those treated with PDGF-BB or NF indicating that
this growth factor may contribute to a more differentiated phenotype compared to other
treatments.
Cells expanded after 14 days of differentiation with NF, PDGF-BB and TGF-β1
showed far fewer cell counts at 28 days of culture, relative to the corresponding 7 day
differentiated cells, suggesting that these cells were significantly more differentiated,
though not quite terminally differentiated as with our SMC cultures. These results align
very closely that of flow cytometry and immunofluorescence analysis in indicating that
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PDGF-BB induces delayed differentiation of BM-MSCs into SMCs unlike TGF-β1,
which achieves this at an earlier time (7 days versus 14 days).
When fold increases in cell number were plotted (Figure 4.18), the fold increases
in cell number for PDGF-BB treated cells was much greater than for the NF cultures,
suggesting lack of differentiation during 7 and 14 day differentiation with PDGF-BB. In
the case of TGF-β1, the proliferation of cells after the differentiation period was slower
than in the corresponding NF cultures, suggesting some degree of phenotypic
change/differentiation had occurred in the short time frame (7 days).
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Figure 4.17. DNA results showing the effect of differentiation time (7 versus 14 day) on cell numbers at
the end of day 28 cultures. Data plotted are average cell numbers ± standard error. Legend: MSC = BMMSCs, SMC = SMCs, NF = BM-MSCs+ NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = BM-MSCs +
TGF-β1, * designates significance of difference between 7 and 14 day differentiation period deemed for p <
0.05.

Comparison
group

Groups that
differ

p-value

SMC 7d

All 7d

0.000

MSC 7d

PDGFbb 7d

0.000

TGFb1 7d

0.000
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PDGFbb 7d

TGFb1 7d

0.000

SMC 14d

All 14d

0.000

MSC 14d

PDGFbb 14d

0.024

TGFb1 14d

0.009

TGFb1 14d

0.010

NF 14d

Table 4.9. Post-Hoc comparison table with p-values indication significance in cell proliferation for cells
cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs
+ NF, PDGFbb = BM-MSCs + PDGF-BB
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Figure 4.18. Fold increases reported for 28-day culture period in cell number for BM-MSCs differentiated
for 7 or 14 days in presence or absence of growth factors. Data plotted represent the mean fold increases ±
standard error. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs+ NF, PDGFbb = BM-MSCs +
PDGF-BB, TGFb1 = BM-MSCs + TGF-β1.

Comparison
group

Groups that
differ

p-value

SMC 7d

All 7d

< 0.05

MSC 7d

All 7d

< 0.05

PDGFbb 7d

0.011

TGFb1 7d

0.003

TGFb1 7d

0.24

NF 7d

PDGFbb 7d
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SMC 14d

All 14d

< 0.05

MSC 14d

PDGFbb 14d

0.012

TGFb1 14d

0.017

PDGFbb 14d

0.010

TGFb1 14d

0.002

TGFb1 14 d

0.022

NF 14d

PGFbb 14d

Table 4.10. Post-Hoc comparison table with p-values indication significance in cell proliferation fold
changes for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs,
NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB

4.7 Fastin assay for elastin quantification
Results obtained from the Fastin assay for both the alkali insoluble and soluble
fractions were normalized to amounts of DNA (indicative of # of cells) obtained from the
fluorometric DNA assay (Section 4.6).
As presented in Figure 4.19, undifferentiated BM-MSCs subjected to 7 and 14
days of pre-culture produce dramatically lower amounts of insoluble elastin compared to
SMCs cultured for the same time period (significance listed in Table 4.11). There seems
to be no difference in the amounts of insoluble elastin produced by BM-MSCs cultured
for 7 days versus 14 days suggesting that longer culture time does not play a role in
enhancing the amounts of insoluble elastin produced by the undifferentiated cells.
Compared to the corresponding undifferentiated BM-MSC controls, BM-MSCs cultured
without any factors on hFN substrates for 7 and 14 days, showed no significant increases
in the amounts of insoluble elastin in the ECM suggesting that a hFN substrate alone
which we showed earlier to coax some degree of differentiation of the BM-MSCs, is
insufficient in coaxing these cells to produce significant amounts of cross-linked matrix
elastin. The treatment of BM-MSCs with PDGF-BB on an hFN substrate for 7 days
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seems to significantly reduce the amounts of insoluble elastin present in the ECM by half
whereas the 14 day treatment appears to significantly enhance these levels. The data
suggests that BM-MSCs treated with PDGF-BB for 14 days may be necessary to enhane
elastin protein production. BM-MSCs treated with TGF-β1 for 7 days produced lower
amounts of cross-linked matrix elastin than did BM-MSCs but produced better amounts
compared with those treated with PDGF-BB or undifferentiated BM-MSCs for the same
duration. Like PDGF-BB, BM-MSCs treated with TGF-β1 for 14 days produced greater
amounts of insoluble elastin than those differentiated for 7 days. This suggests that
although BM-MSCs do not produce the amounts of insoluble cross-linked matrix elastin
as do SMCs cultured for the same period, those differentiated for a longer time point,
seem to produce better results overall.

Insoluble Elastin / DNA [ng/ng]
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Figure 4.19. Insoluble elastin in the extracellular matrix normalized to amounts of DNA obtained from
fluorometric DNA assay. Legend: MSC – BM-MSCs, SMC – SMCs, NF – BM-MSCs = NF, PDGFbb –
BM-MSCs + PDGF-BB, TGFb1 – BM-MSCs + TGF-β1.
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Comparison
group

Groups that
differ

p-value

SMC 7d

All 7d

< 0.05

MSC 7d

PDGFbb 7d

0.007

NF 7d

PDGFbb 7d

0.001

PDGFbb 7d

TGFb1 7d

0.003

SMC 14d

All 14d

< 0.05

NF 14d

PDGFbb 14 d

0.003

Table 4.11. Post-Hoc comparison table with p-values of insoluble elastin for cells cultured or differentiated
for 7 and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BMMSCs + PDGF-BB

Figure 4.20 shows that BM-MSCs subjected to 7 and 14 days of pre-culture
produce dramatically lower amounts of soluble elastin compared to SMCs cultured for
the same time period (significance listed in Table 4.12). BM-MSCs cultured for 14 days
seem to produce twice the amounts of alkali-soluble matrix elastin compared to those
cultured for 7 days suggesting that longer culture time may be required to significantly
enhance elastin pre-cursor production. Compared to the corresponding undifferentiated
BM-MSC controls, BM-MSCs cultured without any factors on hFN substrates, showed
lower amounts of soluble elastin in the ECM suggesting that a hFN substrate alone is
insufficient in coaxing BM-MSCs toward tropoelastin production. The treatment of BMMSCs with PDGF-BB on an hFN substrate for 7 days seems to reduce the amounts of
soluble elastin present in the ECM whereas the same treatment for 14 days appears to
enhance tropoelastin levels. The data suggests that BM-MSCs treated with PDGF-BB for
14 days and not 7 days may be necessary to enhance elastin protein production. BMMSCs treated with TGF-β1 for 7 days produced the same amounts of tropoelastin
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compared to BM-MSCs differentiated in the absence of growth factors but higher
amounts of protein are seen in the 14 day differentiation group. Comparing 7 days versus
14 days of differentiation, it appears from Figure 4.20 that BM-MSCs treated with
growth factors (PDGF-BB and TGF-β1) for 14 days produced more alkali-soluble matrix
elastin than their 7 day differentiated counterparts with TGF-β1 treated cells for 14 days

Alkali-soluble Matrix Elastin /
DNA [ng/ng]

producing the highest amounts of alkali soluble elastin.
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Figure 4.20. Alkali-soluble elastin in the extracellular matrix normalized to amounts of DNA obtained
from fluorometric DNA assay. Legend: MSC – BM-MSCs, SMC – SMCs, NF – BM-MSCs = NF,
PDGFbb – BM-MSCs + PDGF-BB, TGFb1 – BM-MSCs + TGF-β1.

Comparison
group

Groups that
differ

p-value

SMC 7d

All 7d

< 0.05

MSC 7d

PDGFbb 7d

0.013

NF 7d

PDGFbb 7d

0.041

PDGFbb 7d

TGFb1 7d

0.012
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Comparison
group

Groups that
differ

p-value

SMC 14d

All 14d

< 0.05

NF 14d

PDGFbb 14d

0.007

TGFb1 14d

0.022

Table 4.12. Post-Hoc comparison table with p-values of soluble elastin for cells cultured or differentiated
for 7 and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BMMSCs + PDGF-BB

4.8 Hydroxyproline assay for collagen quantification
The hydroxyproline assay results were normalized to cell number obtained from
the fluorometric DNA assay (Section 4.6) to account for variations in initial seeding
density and proliferation rate.
Figure 4.21 shows that BM-MSCs subjected to 7 and 14 days of pre-culture
produce dramatically lower amounts of collagen compared to SMCs cultured for the
same time period (significance listed in Table 4.13). There is no difference in collagen
amounts by BM-MSCs cultured for 7 or 14 days suggesting that longer culture time has
no effect on collagen production in BM-MSCs. Compared to the corresponding
undifferentiated BM-MSC controls, BM-MSCs cultured without any factors on hFN
substrates and TGF-β1 for 7 days, showed significantly higher amounts of ECM
collagen. The treatment of BM-MSCs with PDGF-BB on an hFN substrate for 7 days
seems to increase the amounts of collagen produced whereas the same treatment for 14
days appears to decrease its levels. The data suggests that BM-MSCs treated with PDGFBB for 7 days and not 14 days produce greater amounts of collagen, although data is not
statistically significant. Longer differentiation time in the case of NF and TGF-β1 treated
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cultures seem to significantly produce lower amounts of ECM collagen. Data obtained
from this experiment suggests that differentiation via growth factors alone under the
conditions tested is not enough to coax the differentiated cells to produce the amounts of
elastin necessary for a vascular matrix an elastogenic agent may be necessary to enhance
the outcomes of interest.

Average collagen per cell [pg/cell]

600
500
400
300
200
*

100

*

0
MSC

SMC

NF

7 day differentiation / culture

PDGFbb

TGFb1

14 day differentiation / culture

Figure 4.21. Amounts of collagen normalized to cell count obtained from fluorometric DNA assay in
SMC, BM-MSCs and BM-MSCs differentiated in the presence and absence of growth factors. Legend:
MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 =
BM-MSCs + TGF-β1.

Comparison
group

Groups that
differ

p-value

SMCs 7d

None

> 0.05

MSC 7d

NF 7d

0.023

TGFb1 7d

0.007

All 14d

< 0.05

SMCs 14d

Table 4.13. Post-Hoc comparison table with p-values of collagen for cells cultured or differentiated for 7
and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs +
PDGF-BB
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4.9 LOX activity assay
The LOX activity assay results were normalized to cell number obtained from the
fluorometric DNA assay (Section 4.6) to account for variations in initial seeding density
and proliferation rate.

Average Peroxide [uM]

3.0
2.5
2.0
1.5
1.0
0.5
0.0
MSC

SMC

NF

7 day differentiation / culture

PDGFbb

TGFb1

14 day differentiation / culture

Figure 4.22. Average amounts of peroxide produced by SMC, BM-MSCs and BM-MSCs differentiated in
the presence and absence of growth factors. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs +
NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = BM-MSCs + TGF-β1.

Comparison
group

Groups that
differ

p-value

SMC 7d

MSC 7d

0.008

MSC 7d

All 7d

< 0.05

SMC 14d

MSC 14d

0.019

MSC 14d

All 14d

< 0.05

Table 4.14. Post-Hoc comparison table with p-values of LOX amounts for cells cultured or differentiated
for 7 and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BMMSCs + PDGF-BB
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Although Figure 4.22 shows that both 7 and 14 day undifferentiated BM-MSC
cultures produce the greatest amounts peroxide indicating that these cultures also produce
more LOX than any other treatment group. However, gene expression studies of LOX
(Figure 4.16) and the Fastin elastin assay (Figures 4.19 and 4.20) revealed this group to
have lower gene expression as well as elastin protein production. Therefore, the results of
this assay are inconsistent with previous findings and may need to be further analyzed for
accuracy.
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CHAPTER V
CONCLUSIONS AND RECOMMENDATIONS

5.1 Conclusions
1. Immunohistochemistry data for SMC specific markers showed positive alpha
smooth muscle actin (α-SMA) staining in PDGF-BB and TGF-β1 (7 and 14 day)
treated BM-MSCs compared to those cultured without growth factors. All the
cultures expressed Calponin (expect NF at 7 days) and SM22-α (except NF and
TGF-β1 at 7 days). Quantitative analysis revealed that PDGF-BB increases the
expression of α-SMA per cell in treated BM-MSCs for 7 days when compared to
the other conditions, whereas, TGF-β1 increases the expression of Calponin in 14
day differentiation cultures.
2. Flow cytometry results indicated that BM-MSCs differentiated with TGF-β1,
especially for 14 days more intensely express SMC markers, especially a-SMA
compared to other markers.
3. Cycle cycle analysis indicated that hFN-coated substrate does not affect
differentiation capacity or BM-MSCs and treated with TGF-β1 exhibit a greater
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number of cells in the G1 phase of the cell cycle compared to PDF-BB-treated
BM-MSCs.
4. Real time polymerase chain reaction (RT-PCR) data show higher expression of αSMA in BM-MSCs differentiated for 7 and 14 days with and without cytokines
compared to BM-MSCs. The greatest expression was found in BM-MSCs
differentiated in the absence of cytokines (14 days) and in TGF-β1 cultures
differentiated for 7 days. Elastin gene expression was greatest in the 14 day TGFβ1 treated cultures and there was no difference in gene expression between
treatment or control groups for Caldesmon.
5. Cell proliferation data showed that 7 day differentiation groups had lower cellular
proliferation and BM-MSCs treated with PDGF-BB and TGF-β1 for 14 days had
lower expression compared to others. Comparing the effect of differentiation
time, those cultured for 14 days showed lower cellular proliferation in all groups
except SMCs. Like wise, fold change data exhibited that TGF-β1 treated BMMSCs for both 7 and 14 days were far less proliferative than any other group.
6. Fastin elastin assay showed that BM-MSCs treated with PDGF-BB produced
greater amounts of insoluble and soluble elastin compared to all other groups.
7. Hydroxyproline assay showed no significant differences between BM-MSCs
treated and untreated with cytokines for 7 and 14 day and control cell lines except
SMCs.
8. LOX activity assay showed inconsistent results when compared to RT-PCR data
and fastin elastin assay.
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However, overall evidence from various experiments suggests growth-factor
mediated differentiation into SMC-like cells is possible although terminal differentiation
was not observed under currently tested conditions. The immunofluorescence results of
this study - positive staining for α-SMA, Calponin and SM-22α are consistent with the
findings published by Gong and Niklason48 and Ross J.J. et al33. However, positive
staining for SMMHC was not observed. Results from RT-PCR for α-SMA gene
expression in TGF-β1 treated cultures for 7 days coincide with findings by Ross J.J. et
al33 but, SMMHC gene expression in this study produced opposite results. Investigation
of elastin in ECM produced by BM-MSC derived SMC has been studied by very few
groups if at all any.
5.2 Limitations and recommendations
This study was limited by several factors and the proposed solutions may enhance
the current results obtained.
1. Passage number – The commercially purchased BM-MSCs were of passage 4
(due to availability) and upon propagation became passage 5 for use in
differentiation experiments. Since the protocol provided by the company
recommended using passage 5 or lower for differentiation experiments, the use of
passage 5 in this study may have affected the differentiation outcomes and
perhaps using a lower passage number cell line may have produced better results.
2. Mixed cell population – It may have been possible to have obtained a population
of cells with mixed lineages at the end of the differentiation experiments which
would have drastically affected the outcome observed in this study. To overcome
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this limitation, employing cell sorting and the end of the differentiation phase may
have resulted in a greater population of SMC-like cells.
3. Differentiation time - Since the cell culture period for BM-MSCs were limited to
7 and 14 days, the time may not have been long enough to observe the effect of
cytokines on the differentiation potential. Longer differentiation time may have
produced cells that are closer to the SMC phenotypes. The reversal of
differentiation capability of BM-MSCs after removal of differentiation medium
may have been a possibility and needs to be further assessed.
4. Elastin and Elastic matrix enhancement - During the propagation phase of this
study post differentiation, cells were not treated with exogenous elastin producing
factors such as Hyluronan to facilitate elastic matrix production as demonstrated
previously in our lab52.
5. Growth substrate and compliance – The substrate used for this study was hFN
which, although present in the ECM in vivo to enhance cell adhesion, does not
provide the scaffolding experienced by stem cells in vivo such as collagen and
fibrillin. Using a scaffold with circumferentially aligned fibers may enhance the
production of ECM components, specifically tropoelastin and LOX and aid in the
cross-linking of elastin precursors into the insoluble elastic matrix seen in blood
vessels. Since we tested differentiation on stiff tissue culture plastic, a systematic
examination needs to be conducted to investigate the role of substrate compliance.
Compliant substrates have shown to increase differentiation outcomes.
6. 3-D culture environment – This study was done in a two dimensional (2-D)
microenvironment that does not mimic the native blood vessel environment.
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Perhaps differentiating BM-MSCs in a bioreactor perfused so that to mimic
hemodynamic forces experienced in the body may produce better results in
differentiation and ECM production.
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